N-(Hetero)aryl Substituted Heterocyclic Derivatives Useful for Treating Diseases or Conditions Associated with the Central Nervous System

Abstract

Compounds are provided for use in the treatment or prevention of conditions, diseases, or disorders ameliorated by inhibition of the dopamine transporter. For example, a compound having a piperidine ring represented by the following structural formula is shown. JPEG2023012506000226.jpg40166

Description

[Technical field]

[0001] The present invention relates to heterocyclic derivatives that are inhibitors of the dopamine activated transporter protein (DAT), as well as pharmaceutical compositions containing and uses of such derivatives. [Background technology]

[0002] The spirocyclic derivatives of the present invention are inhibitors of the human dopamine activated transporter protein (DAT) and have numerous therapeutic applications, particularly in the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, Tourette's syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorders, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.

[0003] Dopamine (DA) is a neurotransmitter that plays a fundamental role in cognitive, emotional, motor, motivational, and reward-related functions. Following evoked action potentials, DA is released into the synaptic cleft, and the DA signal is extinguished by reuptake of DA into the presynaptic cell by DAT, amine diffusion via enzymatic degradation, and local metabolism. Dysfunction of the dopaminergic system has been implicated in numerous CNS disorders, and as a result, DAT has become a focus of research for many of these pathologies. There is a strong association between abnormal expression and / or function of DAT and disease.

[0004] Although several commercially available drugs have pharmacological activity at the DAT, none of them are selective and potent DAT inhibitors. Stimulants such as amphetamines and methylphenidate have multiple pharmacological activities, including effects on the levels of DA, noradrenaline (NE), and serotonin (5-HT) in the synapse. In conditions such as ADHD, these stimulants have therapeutic potential, but they also have undesirable side effects, such as abuse potential (1), cardiovascular effects (2), appetite suppression (3), and sleep disturbance (4).

[0005] Other non-selective DAT inhibitors are also used to treat CNS disorders. Bupropion, prescribed as an antidepressant and smoking cessation aid, has a significant DAT component to its pharmacological activity, but is associated with an increased risk of seizures. Similarly, modafinil, prescribed to treat narcolepsy, excessive daytime sleepiness, and shift work sleep disorder, has been shown to inhibit the DAT as part of its pharmacological mechanism of action. Multiple compounds have been developed that selectively target other monoamine transporters, either as inhibitors of the serotonin transporter (SERT) (citalopram, fluoxetine) or as noradrenaline transporter (NET) inhibitors (atomoxetine, reboxetine), as well as dual serotonin / noradrenaline reuptake inhibitors (venlafaxine). Drugs that inhibit SERT and NET suffer from multiple adverse side effects, such as nausea (5), sexual dysfunction (6), and increased suicide risk (7) in the case of drugs that increase 5-HT levels, and elevated pulse rate and blood pressure in the case of drugs that increase noradrenaline levels (8, 9). This makes selective and potent DAT inhibitors, with a neurochemical profile quite distinct from that of stimulants, highly desirable compounds for the treatment of CNS disorders.

[0006] ADD and ADHD are neurodevelopmental mental, behavioral, and cognitive disorders characterized by poor concentration, inner restlessness / hyperactivity, and impulsivity. They are the most common behavioral disorders in children, with a prevalence of 5-10% in the population. The symptoms of these disorders are widely believed to result from dopamine and / or noradrenaline hypofunction. There is a wealth of information indicating that the core symptoms of ADHD are influenced by alterations in dopaminergic function (10), so DAT inhibitors, which would increase synaptic DA levels, should be effective. Current treatments for ADD / ADHD include the stimulants amphetamine and methylphenidate. These compounds have, among other activities, pharmacological activity at the DAT, and the efficacy of these compounds is believed to derive from increasing DA and NE in the corticostriatal system. However, these drugs are not selective DAT inhibitors and therefore cause a rapid, instantaneous, and pronounced release of DA from synaptic terminals, which is associated with the undesirable side effects of these drugs, such as their abuse potential. This neurochemical profile differs from that of selective and potent DAT inhibitors, which produce slower increases in dopamine that are sustained over longer periods of time. This different neurochemical profile is associated with lower reinforcing effects and subsequently lower abuse potential (11). In addition to the neurochemical evidence for the potential therapeutic benefit of DAT inhibitors in ADHD, several studies have shown an association between DAT polymorphisms and overexpression of DAT in ADHD (12). Preclinical models of ADHD symptoms have shown that selective DAT inhibitors, similar to amphetamine and methylphenidate, reduce impulsive behavior in rodents (13), further supporting the potential efficacy of DAT inhibitors. Taken together, this evidence provides compelling data that selective DAT inhibitors may be effective in ADD / ADHD and other disorders characterized by poor impulse control, such as trichotillomania, pathological gambling, kleptomania, and disorders with comorbid impulse control, such as Parkinson's disease.

[0007] Tourette's syndrome is a neuropsychiatric disorder characterized by motor and / or vocal tics. Tourette's syndrome usually appears in childhood and is poorly treated with drugs. Research has proposed that one of the underlying aspects of Tourette's syndrome is dopaminergic dysfunction, whereby tonic / phasic dysfunction leads to reduced synaptic DA levels and consequently higher DA levels in the axon terminals, leading to increased stimulus-dependent release. Further studies have shown that cadaveric tissue from Tourette's syndrome patients has elevated levels of DAT in the frontal lobe (14) and polymorphisms in DAT are associated with the occurrence of Tourette's syndrome. This was further supported in a clinical study of drug-naive children, which showed an increased specific / nonspecific DAT binding ratio in children with Tourette's syndrome (15). These findings suggest that selective DAT inhibitors may provide symptomatic relief for Tourette's syndrome patients.

[0008] Other neuropsychiatric disorders such as obsessive-compulsive disorder (OCD), oppositional defiant disorder (ODD), and conduct disorder have also been associated with DAT. OCD patients have been shown to have an increased specific / nonspecific DAT binding ratio (16), and this ratio was altered after treatment with SSRIs, which are commonly used to treat OCD. Similarly, abnormal dopamine function and / or dopamine turnover have been implicated in ODD, conduct disorder, and other related behavioral disorders (17), and polymorphisms in DAT have been implicated as risk factors for externalizing behavior in children. Studies showing that children with conduct disorder have impaired responses to reinforcement signals and rewards also indicate that modulating synaptic dopamine levels may be a treatment option for these disorders, presenting an opportunity to use selective DAT inhibitors to treat these behavioral disorders.

[0009] Sleep disorders such as narcolepsy, cataplexy, excessive daytime sleepiness, and shift work sleep disorder can interfere with an individual's normal mental and physical health. Some of these disorders are treated with drugs that have pharmacological activity at the DAT. Modafinil is widely used to treat narcolepsy, and its therapeutic potential is related to the occupancy of the DAT. Other treatments for sleep disorders include amphetamine, methamphetamine, and methylphenidate, all of which have pharmacological action at the DAT. Multiple preclinical studies have shown that the wake-promoting effect of some of these compounds and selective DAT inhibitors is abolished in DAT knockout mice. These data overall support the use of selective DAT inhibitors in the treatment of sleep disorders.

[0010] Mood disorders such as major depressive disorder, bipolar depression, seasonal affective disorder, melancholic depression, catatonic depression, postpartum depression, and dysthymia represent a significant medical and social burden to society and are among the most common of all CNS disorders. Treatment for these disorders is currently inadequate due to low levels of efficacy and poor responder rates to currently available therapies. In addition, many of the current standard of care medications result in undesirable side effects. SPECT studies in patients with major depressive disorder have shown that there is increased DAT binding in depressed patients, which is reversed upon successful subsequent antidepressant treatment (18, 19). In addition to this, commercially available antidepressants such as nomifensine have a significant DAT inhibitory component to their mechanism of action. Preclinical studies investigating the behavioral phenotype of DAT knockout mice in tests for antidepressant activity have shown that genetic ablation of DAT function results in antidepressant-like behavior. This evidence supports the therapeutic efficacy of DAT inhibitors in mood disorders.

[0011] A comorbid symptom of depression and an undesirable side effect of many commonly used antidepressants is sexual dysfunction (20). Bupropion, a commonly prescribed antidepressant with a significant DAT inhibitory component to its mechanism of action, has been shown to result in fewer sexual dysfunction-related side effects compared to other antidepressants (21). Furthermore, bupropion has been shown to reverse sexual dysfunction caused by SSRIs. Multiple preclinical studies have shown the effect of bupropion on sexual behavior in rats, which is supported by clinical evidence that the drug is effective in treating women suffering from hypoactive sexual desire disorder. Amphetamine has also been shown to increase sexual behavior in male and female rats and has also been shown to reverse sexual dysfunction in female rats. This evidence of drugs with pharmacological activity at the DAT indicates that selective and potent DAT inhibitors may be suitable therapies for antidepressant-induced sexual dysfunction as well as for the treatment of sexual dysfunction in non-depressed patients.

[0012] DAT polymorphisms have been implicated in anxiety disorders, such as post-traumatic stress disorder (PTSD) (22). Phenelzine, a nonselective monoamine oxidase inhibitor, increases dopamine levels in the brain during its action, and has been shown to reduce symptoms of PTSD. Bupropion, which has a significant DAT inhibitory component to its mechanism of action, is also prescribed for patients with anxiety disorders and has been shown to be effective in patients with panic disorder, supporting the potential of DAT inhibitors in these conditions.

[0013] Movement disorders such as Parkinson's disease (PD) and restless legs syndrome (RLS) are common neurological disorders that are treated with therapies that result in an increase in brain dopamine. PD is characterized by a decrease in dopaminergic neurons in the nigrostriatal pathway and a subsequent decrease in dopamine. Drugs such as L-DOPA, which is converted to dopamine in the brain, have been shown to reduce the motor symptoms of both PD and RLS. Given that DAT inhibitors also increase dopamine levels, it is reasonable to speculate that DAT inhibitors may also provide therapeutic benefit in movement disorders that have been shown to have a dopaminergic component. This hypothesis is further supported by the fact that methylphenidate, a stimulant that has DAT inhibition among its pharmacological activity, has been shown to be clinically effective in motor symptoms (23) and non-motor symptoms (24, 25) in PD patients.

[0014] Addiction and substance abuse are closely related to dopamine and reward circuits in the brain. These substance dependencies include alcoholism, opioid addiction, cocaine addiction, cannabis addiction, amphetamine addiction (or amphetamine-like), hallucinogen addiction, inhalant addiction, polydrug addiction, phencyclidine (or phencyclidine-like) addiction, and nicotine addiction. Preclinical studies with selective DAT inhibitors GBR12909 and other benztropines have shown that these compounds can block the rewarding effects of addictive drugs such as cocaine. GBR12909 has been shown to block the neurochemical effects of cocaine (26, 27) and has also been shown to block the neurochemical effects of amphetamine. Furthermore, compounds that have been demonstrated to be DAT inhibitors are also effective in smoking cessation. This provides evidence that high-affinity selective DAT inhibitors can be effective drugs to block the rewarding effects of addictive drugs and treat addiction.

[0015] Dopamine is also known to play a role in eating disorders, such as binge eating disorder (BED). Eating disorders, such as BED, are known to have multiple components, including impulse control, reward circuits, and cognition, all of which are under the influence of dopaminergic signaling. BED patients are known to have abnormal brain dopamine responses that limit motivation to eat (28). In addition, BED and obese patients show abnormal signaling in the frontal lobe and striatum compared to healthy controls (29). Preclinical models have shown that excitation of the nucleus accumbens, which receives the main dopaminergic input, attenuates binge-eating behavior in rats, and this effect is blocked by dopamine antagonists. This indicates that increasing synaptic dopamine is a potential therapeutic opportunity for eating disorders, such as binge eating disorder. Preclinical data have shown that food intake can be regulated by drugs that modulate synaptic dopamine levels, and specifically by compounds with affinity at the DAT (30). The DAT has been particularly implicated in BED and other eating disorders because polymorphisms in the DAT have been associated with eating disorders (31). This hypothesis is further supported by the efficacy of drugs that have DAT inhibition as part of their mechanism of action in clinical trials for BED and other eating disorders (32). Overall, this supports the therapeutic potential of selective DAT inhibitors in eating disorders such as BED.

[0016] The role of dopamine in cognition is well documented, especially in the cognitive impairment seen in patients suffering from diseases characterized by abnormal dopaminergic signaling, such as Parkinson's disease and schizophrenia. (33) This, combined with the fact that cortical dopamine D1 receptor function is linked to NMDA-mediated glutamate signaling, suggests that enhancement of cognitive processes might be expected with DAT inhibitors.

[0017] Chronic or persistent fatigue is a symptom common to several diseases and can be persistent or recurrent (34). Conditions associated with fatigue include chronic fatigue syndrome, post-viral fatigue syndrome, HIV, multiple sclerosis, amyotrophic lateral sclerosis (ALS), myasthenia gravis, sarcoidosis, cancer, chemotherapy treatment, celiac disease, irritable bowel syndrome, spondyloarthropathy, fibromyalgia, arthritis, infectious diseases, diabetes, eating disorders, Parkinson's disease, sleep disorders, stroke, mood disorders, drug abuse, and alcohol abuse. Clinical studies have shown that several drugs that have DAT inhibition as part of their mechanism of action are effective in combating fatigue in patients with chronic diseases (35). Drugs such as modafinil, methylphenidate, and bupropion, which share DAT inhibition as a common pharmacological mechanism of action, have been shown to be effective in fatigue associated with cancer, chemotherapy, sarcoidosis, ALS, depression, bipolar disorder, multiple sclerosis, Parkinson's disease, HIV, and chronic fatigue syndrome. This evidence supports the potential efficacy of selective and potent DAT inhibitors in fatigue associated with the above-mentioned diseases.

[0018] The multiple potential applications of selective and potent DAT inhibitors have led to numerous chemical families being described in the literature. One particular issue is pharmacological selectivity, with many structural classes of DAT inhibitors described thus far suffering from significant nonspecific pharmacological actions, which have limited their development. One particular issue is the affinity of DAT inhibitors described in the literature for ion channels. Vanoxerine has been shown to have significant activity at multiple ion channels, which has resulted in cardiovascular safety risks that have hindered its development (36). This compound has shown strong functional activity at multiple sodium, calcium, and potassium channels. This would be an undesirable profile for a drug to treat CNS disorders. In addition to nonspecific ion channel pharmacology, DAT inhibitors (especially those of the benztropine class) have been shown to have pharmacological activity at multiple other receptors, such as the serotonin receptor 5-HT2, the muscarinic receptor M1, and the histamine receptor H1 (37, 38, 39). These significant secondary pharmacological activities may result in undesirable side effects for potentially therapeutic DAT inhibitors, making the selectivity profile of the DAT inhibitors particularly important.

[0019] Therefore, there is still a need to develop new DAT inhibitors, especially those that are more selective than noradrenaline and serotonin and have utility in treating a wide range of disorders, especially depression, ADHD, and eating disorders.Preferred compounds have good pharmacokinetic profiles and are particularly suitable as drugs for oral delivery.In addition, particularly preferred compounds show selectivity over noradrenaline and serotonin. Summary of the Invention

[0020] The present invention relates to a series of heterocyclic derivatives that are inhibitors of the DAT. Many of these compounds demonstrate good selectivity for the DAT and are potentially useful in the treatment of sexual dysfunction, affective disorders, anxiety, depression, Tourette's syndrome, Angelman's syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorders, substance abuse (including cocaine abuse and smoking cessation), eating disorders, chronic fatigue, and impulse control disorders. The present invention further relates to pharmaceutical compositions of these inhibitors, the use of these compositions as therapeutic agents, and methods of treatment using these compositions.

[0021] In one embodiment, the present invention provides a compound according to formula I, [ka] During the ceremony, A is selected from phenyl and heteroaryl; B is selected from phenyl and heteroaryl; L is a linker selected from alkylene and O; R 1 is H, alkyl, alkoxy, S-alkyl, S(O) q Alkyl, COR 5 ,CONR 5 R 6 , COOR 5 , C.H. 2 R is selected from OH, OH, F, and Cl; 2 But NR 7 R 8 , C.R. 11 R 12 NR 7 R 8 ,CONR 7 R 8 , (CR 11 R 12 ) 2 NR 7 R 8 , and (CR 11 R 12 ) 3 NR 7 R8 Selected from R 2 But NR 7 R 8 If R 1 is alkyl, alkoxy, CH 2 OH, COR 5 ,CONR 5 R 6 , or COOR 5 and R 3 H, alkyl, alkoxy, NR 7 R 8 , C.H. 2 OH, OH, F, and Cl; or R 2 and R 3 together with the carbon atom to which they are attached form a heterocyclyl or heteroaryl, said heterocyclyl or heteroaryl being selected from N and NR 13 containing at least one ring member selected from 2 and R 3 together with the carbon atom to which they are attached form a heterocyclyl or heteroaryl, provided that L is O; R 1 If is H, then R 2 and R 3 together with the carbon atom to which they are attached form a heterocyclyl, or R 3 is alkyl, alkoxy, NR 7 R 8 , C.H. 2 R is selected from OH, OH, F, and Cl; 4 , R 5 , and R 6 are each independently selected from H and alkyl; R 7 and R 8 are independently H, alkyl, cycloalkyl, heterocyclyl, and C(O)R 10 Selected from R 7 But, C(O)R 10 If R 8 is H or alkyl, or R 7 and R8 may be taken together with the nitrogen atom to which they are attached to form a heterocyclyl, R 9a , R 9b , R 9c , R 9d , R 9e , and R 9f is independently selected from H and alkyl; R 10 is selected from alkyl, aryl, heterocyclyl, and heteroaryl; ---- is absent or represents a bond; and ---- is a bond; R 1 and R 4 is absent, m is 0, 1, or 2, and when m is 2, n is 0, and when n is 2, m is 0, q is 1 or 2, and alkyl is a cyclic alkyl group having up to 6 carbon atoms (C 1 -C 6 ) or straight chain saturated hydrocarbons having 3 to 6 carbon atoms (C 3 -C 6 ) branched saturated hydrocarbons, where alkyl is S-alkyl, S(O)alkyl, S(O) 2 Alkyl, cycloalkyl, heterocyclyl, alkoxy, OH, -CN, CF 3 , COOR 13 ,CONR 13 R 14 , F, Cl, NR 13 COR 14 , and N.R. 13 R 14 and cycloalkyl is an alkyl group having 3 to 7 carbon atoms (C 3 -C 7 ) is a monocyclic saturated hydrocarbon, and cycloalkyl is S-alkyl, S(O)alkyl, S(O) 2 Alkyl, alkyl, alkoxy, OH, -CN, CF 3 , COOR 13 ,CONR 13 R 14 , F, Cl, and NR 13 R 14and phenyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O) 2 Alkyl, OH, F, Cl, -CN, OCF 3 , C.F. 3 , N.R. 13 COR 14 , and N.R. 13 R 14 and the alkylene is optionally substituted with 1, 2, or 3 substituents independently selected from the divalent C 1-3 Linear alkyl radical or divalent C 3-4 Branched alkyl radicals, alkylene includes S-alkyl, S(O)alkyl, S(O) 2 Alkyl, heterocyclyl, alkoxy, OH, -CN, CF 3 , COOR 13 ,CONR 13 R 14 , F, Cl, NR 13 COR 14 , and N.R. 13 R 14 and heterocyclyl, where possible, is selected from N, S, O, and NR 13 and heterocyclyl is an alkyl, cycloalkyl, alkoxy, S-alkyl, S(O)alkyl, S(O) 2 Alkyl, oxo, OH, F, Cl, -CN, OCF 3 , C.F. 3 , N.R. 13 COR 14 , and N.R. 13 R 14 and heteroaryl, where possible, is optionally substituted with 1, 2, or 3 substituents independently selected from N, NR 13Heteroaryl is an aromatic ring having 5 or 6 members, containing 1, 2, or 3 ring members independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O)alkyl, and O; 2 Alkyl, OH, F, Cl, -CN, OCF 3 , C.F. 3 , N.R. 13 COR 14 , and N.R. 13 R 14 and alkoxy is an alkyl group having 1 to 6 carbon atoms (C 1 -C 6 ) straight chain O-bonded hydrocarbons or 3-6 carbon atoms (C 3 -C 6 ) branched O-linked hydrocarbon, and alkoxy is S-alkyl, S(O)alkyl, S(O) 2 Alkyl, alkyl, OH, -CN, CF 3 , COOR 13 ,CONR 13 R 14 , F, Cl, NR 13 COR 14 , and N.R. 13 R 14 and R 11 , R 12 , R 13 , and R 14 is independently selected from H and alkyl, and the compound of formula I is [ka] The present invention provides compounds, which are not:

[0022] In some embodiments, the present invention includes a compound of formula I, wherein R 2 and R 3When together with the carbon atom to which they are attached form a heterocyclyl or heteroaryl, the sum of m and n is 2.

[0023] In one embodiment, the present invention comprises a compound of formula I: R 1 is alkyl, alkoxy, S-alkyl, S(O) q Alkyl, COR 5 ,CONR 5 R 6 , COOR 5 , C.H. 2 selected from OH, OH, F, and Cl; R 2 But NR 7 R 8 ,CONR 7 R 8 , C.R. 11 R 12 NR 7 R 8 , (CR 11 R 12 ) 2 NR 7 R 8 , and (CR 11 R 12 ) 3 NR 7 R 8 is selected from R 3 is selected from H and alkyl; R 4 , R 5 , and R 6 are each independently selected from H and alkyl; ---- is absent.

[0024] In certain embodiments, the present invention includes compounds of formula I, wherein n is 1 and m is 0 or 1.

[0025] In some embodiments, the present invention includes a compound of formula I, wherein R 9a , R 9b , R 9c , R 9d , R 9e , R 9f , R 11, and R 12 are all H.

[0026] In some embodiments, the present invention includes a compound of formula I, according to formula IA: [ka] During the ceremony, A is selected from phenyl and heteroaryl; B is selected from phenyl and heteroaryl; L is a linker selected from alkylene and O; R 1 But, CH 2 selected from OH, OH, F, and Cl; R 7 and R 8 are independently H, alkyl, cycloalkyl, heterocyclyl, and C(O)R 10 Selected from R 7 But, C(O)R 10 If R 8 is H or alkyl, or R 7 and R 8 may be taken together with the nitrogen atom to which they are attached to form a heterocyclyl, R 10 is selected from alkyl, aryl, heterocyclyl, and heteroaryl, m is 0 or 1, and alkyl is a group having up to 6 carbon atoms (C 1 -C 6 ) or straight chain saturated hydrocarbons having 3 to 6 carbon atoms (C 3 -C 6 ) branched saturated hydrocarbon, where alkyl is cycloalkyl, heterocyclyl, S-alkyl, S(O)alkyl, S(O) 2 Alkyl, alkoxy, OH, -CN, CF 3 , COOR 13 ,CONR 13 R 14 , F, Cl, NR 13 COR 14 , and N.R. 13 R 14and cycloalkyl is an alkyl group having 3 to 7 carbon atoms (C 3 -C 7 ) is a monocyclic saturated hydrocarbon, and cycloalkyl is S-alkyl, S(O)alkyl, S(O) 2 Alkyl, alkyl, alkoxy, OH, -CN, CF 3 , COOR 13 ,CONR 13 R 14 , F, Cl, NR 13 COR 14 , and N.R. 13 R 14 and phenyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O) 2 Alkyl, OH, F, Cl, -CN, OCF 3 , C.F. 3 , N.R. 13 COR 14 , and N.R. 13 R 14 and heterocyclyl is, where possible, a saturated or partially unsaturated monocyclic ring containing 1 or 2 ring members independently selected from N, S, O, and NH and 2 to 5 carbon atoms, and heterocyclyl is an alkyl, cycloalkyl, alkoxy, S-alkyl, S(O)alkyl, S(O)alkyl, 2 Alkyl, oxo, OH, F, Cl, -CN, OCF 3 , C.F. 3 , N.R. 13 COR 14 , and N.R. 13 R 14 and heteroaryl, where possible, is optionally substituted with 1, 2, or 3 substituents independently selected from N, NR 13Heteroaryl is an aromatic ring having 5 or 6 members, containing 1, 2, or 3 ring members independently selected from , S, and O; heteroaryl is an alkyl, cycloalkyl, alkoxy, S-alkyl, S(O)alkyl, S(O) 2 Alkyl, OH, F, Cl, -CN, OCF 3 , C.F. 3 , N.R. 13 COR 14 , and N.R. 13 R 14 and alkoxy is an alkyl group having 1 to 6 carbon atoms (C 1 -C 6 ) straight chain O-bonded hydrocarbons or 3-6 carbon atoms (C 3 -C 6 ) branched O-linked hydrocarbon, and alkoxy is S-alkyl, S(O)alkyl, S(O) 2 Alkyl, alkyl, OH, -CN, CF 3 , COOR 13 ,CONR 13 R 14 , F, Cl, NR 13 COR 14 , and N.R. 13 R 14 and R 13 and R 14 is independently selected from H and alkyl, as well as tautomers, stereoisomers (including enantiomers, diastereoisomers, and racemic and scalemic mixtures thereof), pharma- ceutically acceptable salts, and solvates thereof.

[0027] In certain embodiments, the present invention includes compounds of formula I, wherein m is 1.

[0028] In some embodiments, the present invention includes a compound of formula I, wherein R 1 is OH.

[0029] In certain embodiments, the present invention includes compounds of formula I, wherein L is O.

[0030] In certain embodiments, the present invention includes compounds of formula I, wherein A is phenyl, pyridyl, or pyrimidinyl, and is selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O) 2 Alkyl, OH, F, Cl, -CN, OCF 3 , C.F. 3 , N.R. 13 COR 14 , and N.R. 13 R 14 and optionally substituted with 1, 2, or 3 substituents independently selected from:

[0031] In certain embodiments, the present invention includes compounds of formula I, wherein A is phenyl, 2-pyridyl, or 1,3-pyrimidinyl, and is selected from alkyl, F, Cl, -CN, and CF. 3 and optionally substituted with 1, 2, or 3 substituents independently selected from:

[0032] In certain embodiments, the present invention includes compounds of formula I, wherein A is selected from the group consisting of: [ka] [ka]

[0033] In certain embodiments, the present invention includes compounds of formula I, wherein B is phenyl and is selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O) 2 Alkyl, OH, F, Cl, -CN, OCF 3 , C.F. 3 , N.R. 13 COR 14 , and N.R. 13 R 14 and optionally substituted with 1, 2, or 3 substituents independently selected from:

[0034] In certain embodiments, the invention includes compounds of formula I, wherein B is selected from the group consisting of: [ka]

[0035] In one aspect, the present invention provides a compound selected from Examples 1-39. In yet another aspect, the present invention provides an N-oxide of a compound of formula I, as defined herein, or a prodrug or a pharma- ceutically acceptable salt thereof.

[0036] It will be understood that certain compounds of the present invention may exist in solvated, for example hydrated, forms as well as unsolvated forms, and it is to be understood that the present invention encompasses all such solvated forms. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0037] In certain embodiments, the present invention provides a subset of compounds of formula I, defined by formula IB: [ka] During the ceremony, A is selected from phenyl and heteroaryl; B is selected from phenyl and heteroaryl; L is a linker selected from alkylene and O; R 1 But, CH 2 OH and R 2 But NR 7 R 8 or R 1 is selected from OH, F, and Cl; R 2 But, CH 2 NR 7 R 8 R 7 and R 8are independently H, alkyl, cycloalkyl, heterocyclyl, and C(O)R 10 Selected from R 7 But, C(O)R 10 If R 8 is H, or R 7 and R 8 may be taken together with the nitrogen atom to which they are attached to form a heterocyclyl, R 10 is selected from alkyl, aryl, heterocyclyl, and heteroaryl, m is 0 or 1, and alkyl is a group having up to 6 carbon atoms (C 1 -C 6 ) or straight chain saturated hydrocarbons having 3 to 6 carbon atoms (C 3 -C 6 ) branched saturated hydrocarbon, where alkyl is cycloalkyl, heterocyclyl, S-alkyl, S(O)alkyl, S(O) 2 Alkyl, alkoxy, OH, -CN, CF 3 , COOR 13 ,CONR 13 R 14 , F, Cl, NR 13 COR 14 , and N.R. 13 R 14 and cycloalkyl is an alkyl group having 3 to 7 carbon atoms (C 3 -C 7 ) is a monocyclic saturated hydrocarbon, and cycloalkyl is S-alkyl, S(O)alkyl, S(O) 2 Alkyl, alkyl, alkoxy, OH, -CN, CF 3 , COOR 13 ,CONR 13 R 14 , F, Cl, NR 13 COR 14 , and N.R. 13 R 14 and phenyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O) 2Alkyl, OH, F, Cl, -CN, OCF 3 , C.F. 3 , N.R. 13 COR 14 , and N.R. 13 R 14 and heterocyclyl is, where possible, a saturated or partially unsaturated monocyclic ring containing 1 or 2 ring members independently selected from N, S, O, and NH and 2 to 5 carbon atoms, and heterocyclyl is an alkyl, cycloalkyl, alkoxy, S-alkyl, S(O)alkyl, S(O)alkyl, 2 Alkyl, oxo, OH, F, Cl, -CN, OCF 3 , C.F. 3 , N.R. 13 COR 14 , and N.R. 13 R 14 and heteroaryl, where possible, is optionally substituted with 1, 2, or 3 substituents independently selected from N, NR 13 Heteroaryl is an aromatic ring having 5 or 6 members, containing 1, 2, or 3 ring members independently selected from , S, and O; heteroaryl is an alkyl, cycloalkyl, alkoxy, S-alkyl, S(O)alkyl, S(O) 2 Alkyl, OH, F, Cl, -CN, OCF 3 , C.F. 3 , N.R. 13 COR 14 , and N.R. 13 R 14 and alkoxy is an alkyl group having 1 to 6 carbon atoms (C 1 -C 6 ) straight chain O-bonded hydrocarbons or 3-6 carbon atoms (C 3 -C 6 ) branched O-linked hydrocarbon, and alkoxy is S-alkyl, S(O)alkyl, S(O) 2 Alkyl, alkyl, OH, -CN, CF 3 , COOR 13 ,CONR 13 R 14, F, Cl, NR 13 COR 14 , and N.R. 13 R 14 and R 13 and R 14 is independently selected from H and alkyl, as well as tautomers, stereoisomers (including enantiomers, diastereoisomers, and racemic and scalemic mixtures thereof), pharma- ceutically acceptable salts, and solvates thereof.

[0038] The present invention also includes the following aspects and combinations thereof:

[0039] In some embodiments, A is selected from phenyl, pyrazinyl, pyridyl, and pyrimidinyl, and is selected from alkyl, cycloalkyl, alkoxy, S-alkyl, OH, F, Cl, -CN, OCF 3 , C.F. 3 , and N.R. 13 R 14 and optionally substituted with 1, 2, or 3 substituents independently selected from:

[0040] In some embodiments, A is selected from phenyl, pyridyl, and pyrimidinyl; alkyl, cycloalkyl, alkoxy, S-alkyl, F, -CN, and CF 3 and optionally substituted with 1, 2, or 3 substituents independently selected from:

[0041] In some embodiments, A is selected from phenyl, 2-pyridyl, and 1,3-pyrimidinyl; alkyl, cycloalkyl, alkoxy, S-alkyl, F, -CN, and CF 3 and optionally substituted with 1, 2, or 3 substituents independently selected from:

[0042] In some embodiments, A is selected from the group consisting of alkyl, cycloalkyl, alkoxy, S-alkyl, F, -CN, and CF. 3and n is 0, 1, 2, or 3; and n is 0, 1, 2, or 3.

[0043] In some embodiments, B is alkyl, cycloalkyl, alkoxy, S-alkyl, OH, F, Cl, -CN, OCF 3 , C.F. 3 , and N.R. 13 R 14 and n is 0, 1, 2, or 3.

[0044] In some embodiments, B is alkyl, alkoxy, OH, F, Cl, -CN, OCF 3 , and C.F. 3 and n is 0, 1, 2, or 3.

[0045] In some embodiments, B is unsubstituted phenyl, or F, -CN, and CH 3 and n is 1 or 2.

[0046] In some embodiments, B is phenyl substituted with one F substituent. In some embodiments, B is meta-fluoro-phenyl.

[0047] In one embodiment, R 1 is H, alkyl, alkoxy, CH 2 selected from OH, OH, F, and Cl; R 2 is NR 7 R 8 , C.R. 11 R 12 NR 7 R 8 , (CR 11 R 12 ) 2 NR 7 R 8 , and (CR 11 R 12 ) 3 NR 7 R8 Selected from R 3 is selected from H and alkyl, or R 2 and R 3 together with the carbon atom to which they are attached form a heterocyclyl or heteroaryl, the heterocyclyl or heteroaryl being selected from N and NR 13 containing at least one ring member selected from However, R 2 and R 3 together with the carbon atom to which they are attached form a heterocyclyl or heteroaryl, provided that L is O; And R 1 If H, then R 2 and R 3 provided that, together with the atom to which they are attached, they form a heterocyclyl.

[0048] In one embodiment, R 1 is alkyl, alkoxy, CH 2 selected from OH, OH, F, and Cl; R 2 is NR 7 R 8 , C.R. 11 R 12 NR 7 R 8 , (CR 11 R 12 ) 2 NR 7 R 8 , and (CR 11 R 12 ) 3 NR 7 R 8 is selected from R 3 is selected from H and alkyl; R 4 , R 5 , and R 6 are each independently selected from H and alkyl; ---- is absent.

[0049] In one embodiment, R 1 is H, alkyl, alkoxy, CH 2 is selected from OH, OH, F, and Cl.

[0050] In one embodiment, R 1 is CH 2 is selected from OH, OH, F, and Cl.

[0051] In one embodiment, R 1 is selected from OH, F, and Cl.

[0052] In one embodiment, R 1 is OH or F.

[0053] In one embodiment, R 1 is OH.

[0054] In one embodiment, R 2 is NR 7 R 8 , C.R. 11 R 12 NR 7 R 8 , (CR 11 R 12 ) 2 NR 7 R 8 , and (CR 11 R 12 ) 3 NR 7 R 8 Selected from R 2 But NR 7 R 8 If R 1 is alkyl or CH 2 It is OH.

[0055] In one embodiment, R 2 is NR 7 R 8 or CH 2 NR 7 R 8 It is.

[0056] In one embodiment, R2 is CH 2 NR 7 R 8 In some embodiments, R 2 is CH 2 NH 2 It is.

[0057] In certain embodiments, L is methylene, ethylene, or O.

[0058] In certain embodiments, L is methylene or O.

[0059] In certain embodiments, L is O.

[0060] In one embodiment, R 9a-f are all H. In some embodiments, R 13 is H. In some embodiments, R 14 is H.

[0061] In certain embodiments, m is 0 or 1 and n is 0 or 1.

[0062] In some embodiments, n is 1 and m is 0 or 1. In some embodiments, n is 1 and m is 1.

[0063] In one embodiment, R 3 and R 4 is independently selected from H and alkyl.

[0064] In one embodiment, R 3 and R 4 is H.

[0065] In one embodiment, R 7 and R 8 are independently H, alkyl, cycloalkyl, heterocyclyl, and C(O)R 10 Selected from R 7 But, C(O)R 10 If R 8 is H, or R 7 and R8 together with the nitrogen atom to which they are attached may form a heterocyclyl.

[0066] In some embodiments, q is 2.

[0067] In one embodiment, NR 7 R 8 is selected from the following: [ka]

[0068] In certain embodiments, the invention includes a subset of compounds of formula I selected from the following: [ka]

[0069] In certain embodiments, the ALB is selected from the following: [ka] [ka] During the ceremony, Each R 15 are independently H and R 17 0, 1, 2, or 3 R 15 is R 17 And each R 16 are independently H and R 17 0, 1, 2, or 3 R 16 is R 17 And each R 17 are independently alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O) 2 Alkyl, OH, F, Cl, -CN, OCF 3 , C.F. 3、 NR 13 COR14 , and N.R. 13 R 14 is selected from.

[0070] In certain embodiments, A is selected from the following: [ka] [ka] [ka] [ka]

[0071] In certain embodiments, B is selected from the following: [ka] [ka] [ka]

[0072] In certain embodiments, the ALB is selected from the following: [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka]

[0073] Preferably, the ALB is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (j), (k), (m), (n), (s), (x), (y), (dd), (ee), (ll), (nn), (pp), (ss), (bbb), (ggg), (hhh), and (jjj). More preferably, the ALB is selected from the group consisting of (a), (b), (c), (k), (n), and (dd).

[0074] In one aspect, the present invention provides a method for producing a pharmaceutical composition comprising: 4-[(dimethylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol, 1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-(pyrrolidin-1-ylmethyl)piperidin-4-ol, 4-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol, 4-{[cyclopropyl(methyl)amino]methyl}-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol, 1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-[(methylamino)methyl]piperidin-4-ol, 4-[(3,3-difluoropyrrolidin-1-yl)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol, 4-(1,4-diazepan-1-ylmethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol, 4-[(2,5-dimethylpyrrolidin-1-yl)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol, 4-[(tert-butylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol, 1-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)pyrrolidin-2-one, 4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol, {4-fluoro-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl}methanamine, 4-(aminomethyl)-1-[3-fluoro-5-(3-fluorophenoxy)phenyl]piperidin-4-ol, 4-(aminomethyl)-1-[2,5-difluoro-3-(3-fluorophenoxy)phenyl]piperidin-4-ol, 4-(aminomethyl)-1-(2-fluoro-3-phenoxyphenyl)piperidin-4-ol, 4-(aminomethyl)-1-[2-fluoro-3-(3-fluorophenoxy)phenyl]piperidin-4-ol, 4-(aminomethyl)-1-[2,3-difluoro-5-(3-fluorophenoxy)phenyl]piperidin-4-ol, 4-(aminomethyl)-1-[3,4-difluoro-5-(3-fluorophenoxy)phenyl]piperidin-4-ol, {4-amino-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl}methanol, N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-2-methylpropanamide, 2-cyclopropyl-N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)acetamide, N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-2-(propan-2-yloxy)acetamide, N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)acetamide, N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)azetidine-3-carboxamide, N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)benzamide, N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-1H-pyrazole-4-carboxamide, N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)pyrazine-2-carboxamide, 2-amino-N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)acetamide, 3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol, (3S)-3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol, (3R)-3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol, 3-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol, N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)-2-methylpropanamide, N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)azetidine-3-carboxamide, 4-(3-fluorophenoxy)-2-{3H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl}-6-(trifluoromethyl)pyrimidine, and 6-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-decahydro-1,6-naphthyridine, as well as pharma- ceutically acceptable salts and solvates thereof. 4-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol, 1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-[(methylamino)methyl]piperidin-4-ol, 4-(1,4-diazepan-1-ylmethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol, 4-[(tert-butylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol, 4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol, {4-fluoro-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl}methanamine, 4-(aminomethyl)-1-[3-fluoro-5-(3-fluorophenoxy)phenyl]piperidin-4-ol, 4-(aminomethyl)-1-[2,5-difluoro-3-(3-fluorophenoxy)phenyl]piperidin-4-ol, 4-(aminomethyl)-1-(2-fluoro-3-phenoxyphenyl)piperidin-4-ol, 4-(aminomethyl)-1-[2-fluoro-3-(3-fluorophenoxy)phenyl]piperidin-4-ol, 4-(aminomethyl)-1-[2,3-difluoro-5-(3-fluorophenoxy)phenyl]piperidin-4-ol, 4-(aminomethyl)-1-[3,4-difluoro-5-(3-fluorophenoxy)phenyl]piperidin-4-ol, {4-amino-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl}methanol, N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-2-methylpropanamide, 2-cyclopropyl-N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)acetamide, N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-2-(propan-2-yloxy)acetamide, N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)acetamide, N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)azetidine-3-carboxamide, N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)benzamide, N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-1H-pyrazole-4-carboxamide, N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)pyrazine-2-carboxamide, 2-amino-N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)acetamide, 3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol, (3S)-3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol, (3R)-3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol, 3-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol, N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)azetidine-3-carboxamide, 4-(3-fluorophenoxy)-2-{3H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl}-6-(trifluoromethyl)pyrimidine, and pharma- ceutically acceptable salts and solvates thereof.

[0075] therapeutic use As mentioned above, the compounds of the present invention are potent inhibitors of the dopamine transporter, and are therefore useful in the treatment of disease conditions in which hyperactivity of the dopamine transporter is a causative factor.

[0076] The compounds of the present invention are preferably selective for the dopamine transporter over the noradrenaline transporter and the serotonin transporter.In this context, the word "selective" means that the compound has an IC50 value that is at least 10 times more selective for the dopamine transporter than each of the noradrenaline transporter and the serotonin transporter, and preferably has an IC50 value that is at least 20 times, more preferably at least 30 times, even more preferably 50 times, and most preferably 100 times higher for the dopamine transporter than each of the noradrenaline transporter and the serotonin transporter.

[0077] Thus, the present invention provides compounds of formula I for use in therapy.

[0078] The invention also provides the use of a compound of formula I in the manufacture of a medicament for the treatment or prevention of a condition, disease, or disorder that is ameliorated by inhibition of the dopamine transporter.

[0079] The present invention also provides compounds of formula I for use in the treatment or prevention of conditions, diseases, or disorders that are ameliorated by inhibition of the dopamine transporter.

[0080] The present invention also provides a method for treating a condition, disease, or disorder ameliorated by inhibition of the dopamine transporter, the method comprising administering to a subject in need of treatment an effective amount of a compound of formula I.

[0081] In one aspect, conditions, diseases, or disorders ameliorated by inhibition of the dopamine transporter include sexual dysfunction, affective disorders, anxiety, depression, Tourette's syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorders, substance abuse (including smoking cessation), eating disorders, chronic fatigue, and impulse control disorders.

[0082] In certain embodiments, the condition, disease, or disorder is selected from ADD, ADHD, and binge eating disorder.

[0083] In the context of the present invention, references herein to "treatment" include references to curative treatment, palliative treatment and prophylactic treatment.

[0084] As used herein, the term "therapeutically effective amount" means an amount of an active compound or pharmaceutical agent that elicits in a tissue system, animal, or human the biological or medicinal response desired by a researcher, veterinarian, physician, or other clinician, including amelioration of the symptoms of the disease or disorder being treated.

[0085] Combination therapy When combination therapy is employed, the compound of the present invention and the combination may be in the same pharmaceutical composition or in different pharmaceutical compositions and may be administered separately, sequentially or simultaneously.

[0086] The compounds of the present invention may be administered in combination with at least one other active pharmaceutical ingredient for the treatment of mood disorders, such as depression, refractory depression, bipolar depression, and psychotic depression. Such pharmaceutical combinations may be in the form of a unit dosage form or in the form of a package containing the at least two active ingredients separately. In a further aspect, the present invention relates to such pharmaceutical combinations.

[0087] Therefore, in a further aspect, the present invention relates to a pharmaceutical combination comprising an effective amount of a compound of the invention and a second active agent, for simultaneous or sequential administration.

[0088] In certain aspects, the present invention relates to a compound of the present invention in combination with another therapeutic agent, the other therapeutic agent being a tricyclic antidepressant (amitriptyline, clomipramine, doxepin, imipramine, trimipramine, desipramine, nortriptyline, protriptyline), a tetracyclic antidepressant (amoxapine, maprotiline, mazindol, mianserin, mirtazapine, setiptiline), a selective serotonin reuptake inhibitor (citalopram, ezetimibe), a cyclosporine (cyclosporine ... sucitalopram, paroxetine, fluoxetine, fluvoxamine, sertraline), serotonin antagonists and reuptake inhibitors (etoperidone, nefazodone, trazodone), selective norepinephrine reuptake inhibitors (atomoxetine, reboxetine, viloxazine), serotonin and norepinephrine reuptake inhibitors (desvenlafaxine, duloxetine, milnacipran, venlafaxine), monoamine acids Metabolic enzyme inhibitors (isocarboxazid, phenelzine, selegiline, tranylcypromine, moclobemide, pirlindole), mood stabilizers (lithium, valproate, lamotrigine, carbamazepine, oxcarbazepine), and / or antipsychotics (clozapine, olanzapine, risperidone, quetiapine, ziprasidone, amisulpride, asenapine, paliperidone, iloperidone, zotepine, sertindole, lurazil, serotin ... sidone, aripiprazole, haloperidol, droperidol, chlorpromazine, fluphenazine, perphenazine, prochlorperazine, thioridazine, trifluoperazine, mesoridazine, pericyazine, promazine, triflupromazine, levomepromazine, promethazine, pimozide, cyamemazine, chlorprothixene, clopenthixol, flupenthixol, thiothixene, zuclopenthixol).

[0089] In addition to treating primary symptoms or therapeutic lag periods, DAT inhibitors may be used adjunctively to treat drug-induced sedation, a common side effect of antidepressant therapy, particularly selective serotonin reuptake inhibitors (SSRIs), common in disorders such as bipolar depression and sexual dysfunction.

[0090] The compound of the present invention may be administered in combination with at least one other active pharmaceutical ingredient for the treatment of smoking cessation and the alleviation of nicotine withdrawal symptoms and weight gain.Such pharmaceutical combination may be in the form of a unit dosage form or in the form of a package that contains these at least two active ingredients separately.In a further aspect, the present invention relates to such pharmaceutical combination.

[0091] Therefore, in a further aspect, the present invention relates to a pharmaceutical combination comprising an effective amount of a compound of the invention and a second active agent, for simultaneous or sequential administration.

[0092] In certain aspects, the present invention relates to a compound of the present invention in combination with another therapeutic agent, said other therapeutic agent being selected from the following:

[0093] Selected from nicotine replacement therapies (nicotine patch, nicotine gum, nicotine spray, nicotine sublingual tablets, nicotine lozenges, and nicotine inhalers), nicotinic full / partial agonists (nicotine, varenicline, lobeline), and opioid agonists / inverse agonists (naloxone, naltrexone, buprenorphine).

[0094] The compound of the present invention may be administered in combination with at least one other active pharmaceutical ingredient for the treatment of ADHD. Such pharmaceutical combination may be in the form of a unit dosage form or in the form of a package containing the at least two active ingredients separately. In a further embodiment, the present invention relates to such pharmaceutical combination.

[0095] Therefore, in a further aspect, the present invention relates to a pharmaceutical combination comprising an effective amount of a compound of the invention and a second active agent, for simultaneous or sequential administration.

[0096] In certain embodiments, the present invention relates to a compound of the present invention in combination with another therapeutic agent, wherein the other therapeutic agent is selected from norepinephrine reuptake inhibitors (atomoxetine, reboxetine, viloxazine), alpha adrenergic receptor agonists (guanfacine, clonidine).

[0097] The compounds of the present invention may be administered in combination with at least one other active pharmaceutical ingredient for the treatment of movement disorders such as Parkinson's disease and restless legs syndrome. Such pharmaceutical combinations may be in the form of a unit dosage form or in the form of a package containing the at least two active ingredients separately. In a further embodiment, the present invention relates to such pharmaceutical combinations.

[0098] Therefore, in a further aspect, the present invention relates to a pharmaceutical combination comprising an effective amount of a compound of the invention and a second active agent, for simultaneous or sequential administration.

[0099] In certain embodiments, the present invention relates to a compound of the present invention in combination with another therapeutic agent, the other therapeutic agent being selected from dopamine precursors (L-dopa), dopamine agonists (levodopa-carbidopa, levodopa-benserazide), dopaminergic anticholinergics (amantadine), anticholinergics (trihexyphenidyl, benztropine, ethopropazine, or procyclidine), dopamine agonists (apomorphine, bromocriptine, cabergoline, lisuride, pergolide, pramipexole, or ropinirole), MAO-B (monoamine oxidase B) inhibitors (selegiline, rasagiline, or deprenyl), COMT (catechol-O-methyltransferase) inhibitors (tolcapone or entacapone).

[0100] definition "Alkyl" is defined above and includes saturated hydrocarbon residues, including: - Up to 6 carbon atoms (C 1 -C 6 ), or up to four carbon atoms (C 1 -C4 ) straight chain groups. Examples of such alkyl groups include 1 -Methyl, C 2 -Ethyl, C 3 -propyl, and C 4 Examples of suitable aryl groups include, but are not limited to, -n-butyl. -3 to 6 carbon atoms (C 3 -C 6 ), or up to four carbon atoms (C 3 -C 4 ) branched groups. Examples of such alkyl groups include 3 -iso-propyl, C 4 -sec-Butyl, C 4 -iso-butyl, C 4 -tert-butyl, and C 5 -neo-pentyl, each of which is optionally substituted as described above.

[0101] "Cycloalkyl" is as defined above and includes monocyclic saturated hydrocarbons of 3 to 7 carbon atoms, or 3 to 6 carbon atoms, or 3 to 5 carbon atoms, or 3 to 4 carbon atoms. Examples of suitable monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. As described above, cycloalkyl is optionally substituted.

[0102] "Alkylene" is -(CH 2 )-, -(CH 2 ) 2 -, -(CH 2 ) 3 - etc., divalent C 1-3 A straight chain alkyl radical or -CH(CH 3 )CH,CH 2 CH(CH 3 )-, -CH(CH 3 )CH(CH 3 )-, etc., divalent C 3-4 It is a branched alkyl radical. As stated above, the alkylene is optionally substituted.

[0103] "Alkoxy" is defined above and includes O-linked hydrocarbon residues, including: -1 to 6 carbon atoms (C 1 -C 6 ), or 1 to 4 carbon atoms (C 1 -C 4 ) straight chain groups. Examples of such alkoxy groups are 1 -Methoxy, C 2 -Ethoxy, C 3 -n-propoxy, and C 4 -n-butoxy. -3 to 6 carbon atoms (C 3 -C 6 ), or 3 to 4 carbon atoms (C 3 -C 4 ) branched groups. Examples of such alkoxy groups include 3 -iso-propoxy, and C 4 Examples of aryl groups include, but are not limited to, sec-butoxy and tert-butoxy, each of which is optionally substituted as described above.

[0104] "Heteroaryl" is as defined above. Examples of suitable heteroaryl groups include thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, and pyrazinyl, which are optionally substituted as described above. Preferably, heteroaryl is selected from pyridyl, pyrazinyl, pyrimidinyl, and 1,2,4-triazinyl, which are optionally substituted as described above. Unless otherwise stated, pyrimidinyl refers to 1,3-pyrimidinyl. Unless otherwise stated (e.g., by chemical formula), when A is pyrimidinyl, A is attached to the heterocyclic backbone at two positions. Unless otherwise stated, when B is pyrimidinyl, B is attached to L at two positions. "Heterocyclyl" is as defined above. Examples of suitable heterocyclyl groups include aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, imidazolyl, morpholine, thiomorpholine, pyrazolidinyl, piperidinyl, and piperazinyl (optionally substituted as described above).

[0105] The term "O-linked", as in "O-linked hydrocarbon residue", means that the hydrocarbon residue is attached to the remainder of the molecule through an oxygen atom.

[0106] -CN and -CH 2 CH(CH 3 In groups such as )-, the "-" indicates the point of attachment of the substituent to the remainder of the molecule.

[0107] "Pharmaceutically acceptable salt" means a salt that is physiologically or toxicologically acceptable and includes, where appropriate, pharma- ceutically acceptable base addition salts and pharma- ceutically acceptable acid addition salts. For example, (i) when the compound of the invention contains one or more acidic groups, such as a carboxy group, pharma- ceutically acceptable base addition salts which may be formed include sodium, potassium, calcium, magnesium, and ammonium salts, or salts with organic amines, such as diethylamine, N-methyl-glucamine, diethanolamine, or amino acids (e.g., lysine), and the like; (ii) when the compound of the invention contains a basic group, such as an amino group, pharma-ceutically acceptable acid addition salts which may be formed include hydrochloride, hydrobromide, sulfate, phosphate, acetate, citrate, lactate, tartrate, mesylate, succinate, oxalate, phosphate, esylate, tosylate, benzenesulfonate, naphthalenedisulfonate, maleate, adipate, fumarate, hippurate, camphorate, xinafoate, p-acetamidobenzoate, dihydroxybenzoate, hydroxynaphthoate, succinate, ascorbate, oleate, hydrogen sulfate, and the like.

[0108] Hemisalts of acids and bases may also be formed, for example, hemisulfate and hemicalcium salts.

[0109] For an overview on suitable salts, see "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).

[0110] "Prodrug" refers to a compound that is convertible in vivo by metabolic means (e.g., by hydrolysis, reduction, or oxidation) to a compound of the invention. Suitable groups for forming prodrugs are described in 'The Practice of Medicinal Chemistry, 2 ndEd. pp 561-585 (2003), and FJ Leinweber, Drug Metab. Res., 1987, 18, 379.

[0111] The compounds of the present invention may exist in both unsolvated and solvated forms.The term "solvate" is used herein to describe the molecular complex that comprises the compounds of the present invention and one or more stoichiometric amounts of pharma-ceutically acceptable solvent molecules, such as ethanol.The term "hydrate" is employed when the solvent is water.

[0112] The compounds of the present invention may exist in one or more geometric, optical, enantiomeric, diastereomeric, conformational and tautomeric forms, including but not limited to cis and trans, E and Z, R, S and meso, keto and enol forms, and conformational isomers. Unless otherwise stated, a reference to a particular compound includes all such isomeric forms, including racemic and other mixtures thereof. Where appropriate, such isomers can be separated from their mixtures by application or adaptation of known methods (e.g., chromatographic and recrystallization techniques). Where appropriate, such isomers can be prepared by application or adaptation of known methods (e.g., asymmetric synthesis).

[0113] An example of a compound of the invention that exhibits optical isomerism is 3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol. The invention therefore encompasses the enantiomeric forms of this compound as illustrated below. [ka]

[0114] Preferably, when the compound exists as an enantiomer, the enantiomer is present in an enantiomeric excess of about 80% or greater, more preferably in an enantiomeric excess of about 90% or greater, even more preferably in an enantiomeric excess of about 95% or greater, even more preferably in an enantiomeric excess of about 98% or greater, and most preferably in an enantiomeric excess of about 99% or greater. Similarly, when the compound exists as a diastereomer, the diastereomer is present in a diastereomeric excess of about 80% or greater, more preferably in a diastereomeric excess of about 90% or greater, even more preferably in a diastereomeric excess of about 95% or greater, even more preferably in a diastereomeric excess of about 98% or greater, and most preferably in a diastereomeric excess of about 99% or greater.

[0115] General method Compounds of formula I should be evaluated for their biopharmaceutical properties such as solubility (across pH) and solution stability, permeability, etc., to select the most appropriate dosage form and route of administration for the treatment of the presented indication. The compounds may be administered alone or together with one or more other compounds of the invention, or together with one or more other drugs (or any combination thereof). In general, the compounds will be administered as a formulation with one or more pharma- ceutically acceptable excipients. The term "excipient" is used herein to describe any ingredient other than the compound(s) of the invention that may impart either functional properties (i.e., drug release rate control) and / or non-functional properties (i.e., processing aid or diluent) to the formulation. The choice of excipient will depend in large part on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.

[0116] The compounds of the present invention intended for pharmaceutical use can be administered as solids or liquids, such as tablets, capsules, or solutions. Pharmaceutical compositions suitable for the delivery of the compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. For example, such compositions and methods for their preparation can be found in Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company, 1995).

[0117] Thus, the present invention provides pharmaceutical compositions comprising a compound of formula I and a pharma- ceutically acceptable carrier, diluent, or excipient.

[0118] The compound of the present invention can also be directly administered to bloodstream, subcutaneous tissue, muscle or internal organs.Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, ​​intrasternal, intracranial, intramuscular, intrasynovial and subcutaneous administration.Suitable devices for parenteral administration include needle (including microneedle) injector, needleless injector and infusion technique.

[0119] Parenteral formulations are typically aqueous or oily solutions. When the solution is aqueous, the excipients include sugars (including but not limited to glucose, mannitol, sorbitol, etc.), salts, carbohydrates, and buffers (preferably to a pH of 3-9), although for some applications the excipients may be more suitably formulated as sterile non-aqueous solutions or in dry form for use in conjunction with a vehicle such as sterile pyrogen-free water.

[0120] Parenteral formulations may include implants derived from degradable polymers such as polyesters (i.e., polylactic acid, polylactide, polylactide-co-glycolide, polycaprolactone, polyhydroxybutyrate), polyorthoesters, and polyanhydrides. These formulations may be administered through a surgical incision, into subcutaneous tissue, muscle tissue, or directly into a specific organ.

[0121] The preparation of parenteral formulations under sterile conditions, for example, by lyophilization, may be readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

[0122] The solubility of compounds of formula I used in the preparation of parenteral solutions can be increased by the use of appropriate formulation techniques, such as the incorporation of cosolvents and / or solubility enhancers, such as surfactants, micellar structures, and cyclodextrins.

[0123] In one embodiment, the compounds of the invention may be administered orally, which may involve swallowing, so that the compound enters the digestive tract, and / or by buccal, lingual, or sublingual administration, which allows the compound to enter the bloodstream directly from the mouth.

[0124] Formulations suitable for oral administration include solid plugs such as tablets, solid microparticles, semisolids and liquids (including multiple phases or dispersions); soft or hard capsules containing multiparticulates or nanoparticles, liquids, emulsions, or powders; lozenges (including those filled with liquid); chewables; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal / mucoadhesive patches.

[0125] Formulations suitable for oral administration may also be designed to deliver the compounds of the present invention in an immediate release or rate-sustained manner, and the release profile may be delayed, pulsatile, controlled, sustained, or delayed and sustained, or modified in such a manner as to optimize the therapeutic effect of the compound. Means of delivering compounds in a rate-sustained manner are known in the art and include slow release polymers that can be formulated with the compounds to control the release of the compounds.

[0126] Examples of rate-sustaining polymers include degradable and non-degradable polymers that can be used to release the compound by diffusion or a combination of diffusion and polymer erosion. Examples of rate-sustaining polymers include hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, ethylcellulose, sodium carboxymethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, xanthum gum, polymethacrylates, polyethylene oxide, and polyethylene glycol.

[0127] Liquid formulations (including multiple phases and dispersions) include emulsions, solutions, syrups, and elixirs. Such formulations may be presented as fillers in soft or hard capsules (e.g., made of gelatin or hydroxypropylmethylcellulose), typically containing carriers such as water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or suitable oils, and one or more emulsifying agents and / or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.

[0128] The compounds of the invention may also be used in fast dissolving, fast disintegrating dosage forms such as those described in Liang and Chen, Expert Opinion in Therapeutic Patents, 2001, 11(6), 981-986.

[0129] Tablet formulations are discussed by H. Lieberman and L. Lachman in Pharmaceutical Dosage Forms: Tablets, Vol. 1 (Marcel Dekker, New York, 1980).

[0130] For administration to human patients, the total daily dose of the compounds of the invention will of course depend on the form of administration, but will typically range from 0.01 mg to 1000 mg, or 0.1 mg to 250 mg, or 1 mg to 50 mg.

[0131] The total dosage may be administered as a single dose or in divided doses, and may fall outside the typical ranges provided herein, at the discretion of the physician. These dosages are based on an average human subject having a body weight of about 60 kg to 70 kg. A physician can easily determine dosages for subjects having body weights outside this range, such as infants and the elderly.

[0132] Synthesis method The compounds of the present invention can be prepared by using the appropriate materials according to the procedures of the following schemes and examples, and are further illustrated by the specific examples provided herein below. In addition, by utilizing the procedures described herein, a person skilled in the art can easily prepare additional compounds that fall within the scope of the invention claimed herein. However, the compounds illustrated in the examples should not be construed as forming the only type that is considered as the invention. These examples further illustrate the details of the preparation of the compounds of the present invention. A person skilled in the art will easily understand that known variations of the conditions and steps of the following preparation procedures can be used to prepare these compounds.

[0133] The compounds of the present invention may be isolated in the form of their pharma- ceutically acceptable salts, such as those previously described hereinabove.

[0134] In intermediates used in the preparation of the compounds of the present invention, it may be necessary to protect reactive functional groups (e.g., hydroxy, amino, thio, or carboxy) to prevent these intermediates from inadvertently participating in the reaction leading to the formation of the compounds. Conventional protecting groups can be used, for example those described by TW Greene and PG M Huts in "Protective groups in organic chemistry," John Wiley and Sons, 4 th The protecting groups described in the American Chemical Society, Vol. 13, No. 1, 2006, may be used. For example, a common amino protecting group suitable for use in the present invention is tert-butoxycarbonyl (Boc), which is easily removed by treatment with an acid such as trifluoroacetic acid or hydrochloric acid in an organic solvent such as dichloromethane. Alternatively, the amino protecting group may be a benzyloxycarbonyl (Z) group, which may be removed by hydrogenation with a palladium catalyst under a hydrogen atmosphere, or a 9-fluorenylmethyloxycarbonyl (Fmoc) group, which may be removed by a solution of a secondary organic amine such as diethylamine or piperidine in an organic solvent. Carboxyl groups are typically protected as esters such as methyl, ethyl, benzyl, or tert-butyl, all of which may be removed by hydrolysis in the presence of a base such as lithium hydroxide or sodium hydroxide. Benzyl protecting groups may also be removed by hydrogenation with a palladium catalyst under a hydrogen atmosphere, while tert-butyl groups may also be removed by trifluoroacetic acid. Alternatively, trichloroethyl ester protecting groups are removed using zinc in acetic acid. A common hydroxy protecting group suitable for use in the present invention is the methyl ether, and deprotection conditions include refluxing in 48% aqueous HBr for 1-24 hours, or by stirring with borane tribromide in dichloromethane for 1-24 hours. Alternatively, if the hydroxy group is protected as a benzyl ether, deprotection conditions include hydrogenation using a palladium catalyst under a hydrogen atmosphere.

[0135] Compounds according to general formula I can be prepared using conventional synthetic methods, including but not limited to the routes outlined in the schemes below.

[0136] i) Synthesis of heterocyclic systems Scheme A [ka]

[0137] Step 1 Compounds of formula II can be obtained by Corey-Tchaikovsky epoxidation of compound I (commercially available from Sigma-Aldrich) using trimethylsulfoxonium iodide and an inorganic base such as NaH. This is carried out in a suitable solvent such as DMSO, carrying out the reaction at room temperature. The reaction takes about 1 hour to about 2 hours to complete.

[0138] Step 2 Compounds of formula III can be obtained by epoxide ring opening of compound II with a primary amine such as methylamine. This is carried out in a mixture of MeOH / water at room temperature. The reaction takes about 1 hour to about 16 hours to complete.

[0139] Step 3 Compounds of formula IV are obtained by N-protection of compound III under standard literature conditions, for example by reaction with di-tert-butyl dicarbonate. This is carried out in the presence or absence of a suitable base, such as triethylamine, in a suitable solvent, for example DCM, typically at room temperature. The reaction takes about 1 hour to about 16 hours to complete.

[0140] Step 4 Compounds of formula V can be obtained from compound IV by removing the benzyl group by hydrogenolysis, for example using ammonium formate and palladium on carbon at reflux in a suitable solvent such as methanol. The reaction takes about 1 hour.

[0141] Step 5 Compound VI can be obtained from compound V by SnAr displacement with a suitable aryl halide. This is carried out in a suitable aprotic solvent, such as DMSO, in the presence of an inorganic base, such as K2CO3. The reaction proceeds at a temperature range of about 25°C to about 100°C and takes about 1 hour to about 12 hours. Alternatively, compound VI can be obtained from a Buchwald reaction with a suitable aryl halide. This is carried out in the presence of a suitable transition metal catalyst, such as Pd 2 (dba) 3 Suitable ligands such as DavePhos, K 3 PO 4 and the like in a suitable solvent, such as DME. The reaction is carried out at a temperature of about 100° C. to about 110° C. and takes about 12 hours.

[0142] Step 6 Compound VII can be obtained from compound VI by removal of the Boc group under acidic conditions, such as TFA in dichloromethane, typically at room temperature, the reaction taking about 1 hour.

[0143] Step 7 Compound VIII can be obtained from compound VII by coupling with a suitable carboxylic acid, such as isobutyric acid. This is carried out in the presence of coupling agents such as EDC HCl and HOBt, and an organic base, such as TEA. The reaction is typically carried out at room temperature in a suitable solvent, such as dichloromethane. The reaction takes about 3 hours to about 12 hours.

[0144] Step 8 Compound IX can be obtained by treating compound VI with a fluorinating agent such as Deoxofluor®, which is typically carried out at 0° C. in a suitable solvent such as dichloromethane. The reaction takes about 1 hour.

[0145] Step 9 Compound IX can be obtained from compound V by removal of the Boc group under acidic conditions, for example in a solution of TFA in dichloromethane, typically at room temperature. The reaction takes about 1 hour.

[0146] Step 10 Compounds of formula XI can be obtained by epoxide ring opening of compound II with a secondary amine such as pyrrolidine. This is carried out in a mixture of MeOH / water at room temperature. The reaction takes about 2 hours to about 16 hours to complete.

[0147] Step 11 Compounds of formula XII can be obtained from compound X by removing the benzyl group by hydrogenolysis, for example using ammonium formate and palladium on carbon at reflux in a suitable solvent such as methanol. The reaction takes about 1 hour.

[0148] Step 12 Compounds XIII can be obtained from compounds XII by SnAr displacement with an appropriate aryl halide. This can be achieved by the reaction of K 2 CO 3 The reaction is carried out in the presence of an inorganic base such as, for example, 1,2-dichlorophenyl ether, etc. The reaction proceeds in a temperature range of about 45° C. to about 100° C. and takes about 1 hour to about 12 hours.

[0149] Scheme B [ka]

[0150] Step 1 The compound of formula II can be reacted with a suitable reducing agent, e.g. LiAlH 4 Compound I (commercially available from Activate Scientific) can be obtained by reduction of compound I with 1,3-dichloro-2,4-dichloro-1,4-dichloro-2,5-dichloro-1,6 ...

[0151] Step 2 Compounds of formula III can be obtained by N-protection of compound II under standard literature conditions, for example by reaction with di-tert-butyl dicarbonate. This is carried out in the presence of a suitable base, such as triethylamine, in a suitable solvent, for example DCM, typically at room temperature. The reaction takes about 2 hours to complete.

[0152] Step 3 Compounds of formula IV can be obtained from compound III by removing the benzyl group by hydrogenolysis, for example using ammonium formate and palladium on carbon at reflux in a suitable solvent such as methanol. The reaction takes about 1 hour.

[0153] Step 4 Compound V can be obtained from compound V by SnAr displacement with an appropriate aryl halide. This can be done by reacting K 2 CO 3 The reaction is carried out in the presence of an inorganic base such as 1,2-dichlorophenyl ether, etc. The reaction proceeds at a temperature of about 60° C. and takes about 1 hour.

[0154] Step 5 Compound VI can be obtained from compound V by removal of the Boc group under acidic conditions, for example in a solution of TFA in dichloromethane, typically at room temperature. The reaction takes about 1 hour.

[0155] ii) Synthesis of ALB system Scheme 1 [ka]

[0156] Step 1 The compound of formula II can be prepared by the reaction of NaBH 4Compound I, (3-bromophenyl)(phenyl)methanone (commercially available from Sigma-Aldrich), can be obtained by reduction of the compound I, (3-bromophenyl)(phenyl)methanone (commercially available from Sigma-Aldrich), using a suitable reduction system such as 1,2-dichloromethane, etc. This is carried out in a suitable solvent, such as dichloromethane, typically at room temperature. The reaction takes about 12 hours to complete.

[0157] Scheme 2 [ka]

[0158] Step 2 Compound V can be obtained by Ullmann condensation between the desired di-halogen benzene, compound III, such as 1,2-dibromo-4,5-difluorobenzene, and the appropriate phenol, compound IV, such as 3-fluorophenol (both commercially available from Alfa-Aesar and Sigma-Aldrich, respectively), in the presence of a suitable catalyst, such as Cu, and a suitable base, e.g., KOH, at elevated temperatures, typically about 100-150° C. The reaction takes about 14 hours to complete. Alternatively, compound V can be obtained by Ullmann condensation between the desired di-halogen benzene, compound III, such as 1,2-dibromo-4,5-difluorobenzene, and the appropriate phenol, compound IV, such as 3-fluorophenol (both commercially available from Alfa-Aesar and Sigma-Aldrich, respectively), in the presence of a suitable catalyst, such as Cu, and a suitable base, e.g., KOH, at elevated temperatures, typically about 100-150° C. The reaction takes about 14 hours to complete. 2 CO 3 and the like, in a suitable solvent, such as DMSO, at a temperature of 25° C. to about 160° C., the reaction taking about 20 to about 12 hours to complete.

[0159] Scheme 3 [ka]

[0160] Step 3 The compound of formula VIII is Cu(OAc) 2The reaction can be accomplished via Chan-Lam coupling between the desired boronic acid, such as phenylboronic acid, compound VI, and an appropriate phenol, such as 3-bromo-2-fluorophenol, compound VII (both commercially available from Sigma-Aldrichr and Zentek, respectively), in the presence of a suitable catalyst, such as dimethylformamide, a suitable base, such as triethylamine, typically at room temperature. The reaction takes approximately 16 hours to complete.

[0161] Step 4 Compound XI can be prepared by reacting a suitable oxidant such as m-CPBA with BF 3 Et 2 The desired boronic acid, for example phenylboronic acid, compound IX, is reacted with a suitable iodinated benzene, such as iodobenzene, compound X (both commercially available from Sigma-Aldrich), in the presence of O. This is carried out in a suitable solvent, such as dichloromethane. The reaction proceeds at temperatures between 0° C. and room temperature and takes about 45 minutes to complete.

[0162] Step 5 Compound VIII can be obtained from compound XI by reaction with a suitable phenol, compound XII, such as 3-fluorophenol, in a suitable solvent, usually THF, in the presence of a suitable base, such as tBuOK, at temperatures between 0° C. and 40° C. The reaction takes about 1 hour.

[0163] Scheme 4 [ka]

[0164] Step 6 Compound XIV can be prepared by reaction of SOCl in a suitable solvent, such as DMF. 2 This can be obtained by chlorination of the commercially available compound XIII (from Sigma-Aldrich), which is 6-(trifluoromethyl)uracil, by treatment with a suitable chlorinating agent such as 1,2-dichloro-1,4-dichloro-1,4-dichloro-1,5-tetrafluoro-1,6-tetrafluoro-1,7-tetrafluoro-1,8-tetrafluoro-1,9-tetrafluoro-1,9-tetrafluoro-1,1-tetrafluoro-1,1-tetrafluoro

[0165] Scheme 5 [ka]

[0166] Step 7 Compounds of formula XVI can be obtained by chlorination of compound XV, which is 2-chloro-4-(methylthio)pyrimidine (commercially available from Sigma-Aldrich), with N-chlorosuccinimide in the presence of a solution of 2,2,6,6-tetramethylpiperidinylmagnesium chloride lithium chloride complex in THF / toluene, typically at room temperature in a suitable solvent such as THF. The reaction takes 4 hours to complete.

[0167] Scheme 6 [ka]

[0168] Step 8 Compounds of structure XVIII and XIX can be obtained via a SnAr reaction between compound XVII, for example 2,4-dichloro-6-methylpyrimidine (commercially available from Sigma-Aldrich), or prepared in situ, and a suitable partner, such as 3-fluorophenol (commercially available from Sigma-Aldrich), which can be carried out by the reaction of K 2 CO 3 The reaction typically proceeds in an aprotic solvent such as DMSO, at a temperature between 25° C. and 110° C., in the presence of a suitable base such as DMSO. The reaction takes about 20 minutes to about 12 hours to complete.

[0169] Scheme 7 [ka]

[0170] Step 9 Compounds of structure XXI and XXII can be obtained via a SnAr reaction between compound XX, for example 2,6-dichloropyridine (commercially available from Sigma-Aldrich), and a suitable phenol, such as 3-fluorophenol (commercially available from Sigma-Aldrich). 2 CO 3 The reaction typically proceeds in an aprotic solvent such as DMSO, in the presence of a suitable base such as DMSO at a temperature between 25° C. and 103° C. The reaction takes about 2 hours to about 48 hours to complete.

[0171] Scheme 8 [ka]

[0172] Step 10 Compounds of structure XXIV can be obtained via a SnAr reaction between compound XXIII, commercially available from Sigma-Aldrich, and a suitable phenol, such as 3-fluorophenol (commercially available from Sigma-Aldrich), which typically proceeds in an aprotic solvent, such as DMF, in the presence of a suitable base, such as tBuOK, at a temperature of about 90° C. The reaction takes about 2 hours to complete.

[0173] Scheme 9 [ka]

[0174] Step 11 Compound XXVII can be obtained by the reaction between compound XXV, 2,4,6-trichloropyrimidine (commercially available from Sigma-Aldrich), and a Grignard reagent XXVI, such as benzylmagnesium chloride (both commercially available from Sigma-Aldrich). The reaction proceeds at temperatures between -78°C and 20°C and takes approximately 3 hours to complete.

[0175] Step 12 Compound XXVIII can be obtained by treatment of compound XXVII with MeONa, which is freshly obtained in situ by adding NaH in MeOH. The reaction is typically carried out at room temperature in MeOH and takes about 1 hour to complete.

[0176] Scheme 10 [ka]

[0177] Step 13 Compounds of structure XXX can be obtained via a SnAr reaction between compound XXIX, commercially available from Sigma-Aldrich, and a suitable phenol, such as 3-fluorophenol (commercially available from Sigma-Aldrich), which typically proceeds in an aprotic solvent, such as DMF, in the presence of a suitable base, such as cesium carbonate, at a temperature of approximately 80° C. The reaction takes approximately 48 hours to complete. EXAMPLES

[0178] The present invention is further illustrated by the following non-limiting examples. In the following procedures, after each starting material, a reference number to a preparation or example is typically provided. This is provided solely for the purpose of assisting the skilled chemist. The starting material may not necessarily have been prepared from the batch referred to. When reference is made to the use of a "similar or similar" procedure, such a procedure may involve minor modifications, such as reaction temperature, amounts of reagents / solvents, reaction time, work-up conditions, or chromatographic purification conditions, as will be understood by those skilled in the art. All temperatures refer to °C. Proton magnetic resonance (NMR) spectra may typically be recorded on a Varian instrument at 400 or 500 MHz, or on a Bruker instrument at 400 MHz. Chemical shifts are expressed in parts of million (ppm, δ units). Chemical shifts are expressed in parts per million (ppm, δ units) relative to Me used as internal standard. 4They are reported in ppm downfield (δ) from Si and are typically assigned as singlet (s), broad singlet (br.s.), doublet (d), doublet of doublets (dd), doublet of doublet of doublets (ddd), doublet of triplets (dt), triplet (t), triplet of doublets (td), quartet (q), or multiplet (m).

[0179] LCMS may be recorded under the following conditions: DAD chromatographic traces, mass chromatograms, and mass spectra can be acquired on a UPLC / PDA / MS Acquity™ system coupled to a Micromass ZQ™ or Waters SQD single quadrupole mass spectrometer operating in positive and / or negative ES ionization mode. Two QC methods were used, one operated at low pH conditions and the other at high pH conditions. Details of the method operated at low pH conditions were as follows: Column, Acquity BEH C 18 , 1.7μm, 2.1×50mm or Acquity CSH C 18 The column temperature was 40°C; eluent A was Milli-Q water + 0.1% HCOOH, and eluent B was MeCN + 0.1% HCOOH. The flow rate was 1 ml / min. The gradient table was 97%A-3%B at t = 0 min, 0.1%A-99.9%B at t = 1.5 min, 0.1%A-99.9%B at t = 1.9 min, and 97%A-3%B at t = 2 min. The UV detection range was 210-350 nm, and the ES + / ES - The range was 100-1000 amu. The details of the method run at high pH conditions were the same as those listed above for the low pH method, with the following exceptions: Column, Acquity BEH C 18 , 1.7 μm, 2.1 × 50 mm; development phase solvent A was NH 4 HCO 3 The developing solvent B was MeCN.

[0180] Semipreparative mass spectrometer-directed autopurification (MDAP) was performed using a Waters Fractionlynx™ system operating under low or high pH chromatographic conditions. The stationary phases used were XTerra C18, XBridge C18, Sunfire C18, XSelect C18, Gemini AXIA C18. The column length was 5, 10, or 15 cm, while the internal diameter was 19, 21, or 30 mm. The particle size of the stationary phase was 5 or 10 μm. Purification was performed using low or high pH chromatographic conditions. The solvent composition of the developing phase was the same as that used for the QC analysis. The stationary phase / developing phase combinations used were XTerra, XBridge, Sunfire, XSelect for low pH developing phase, and XTerra, XBridge, Gemini for high pH developing phase. AXIA. All purifications were performed with the column held at room temperature. The flow rates used were 17 or 20 ml / min for the 19 or 21 mm ID columns and 40 or 43 ml / min for the 30 mm ID columns. The trigger for collection of the target species was the presence of the target m / z ratio value in the TIC MS signal. The gradient timetable was customized according to the Rt behavior of the target species.

[0181] Purification may also be performed using Biotage® Isolera or Biotage® SP1 flash chromatography systems, which operate with Biotage® KP-SIL and Biotage® KP-NH cartridges. Unless otherwise stated, all reactions are typically carried out under an inert atmosphere (e.g., nitrogen).

[0182] The following abbreviations are used in the text: EtOAc, AcOEt, EA = ethyl acetate, Et 2O = diethyl ether, MeOH = methanol; THF = tetrahydrofuran, Tlc refers to thin layer chromatography on silica plates, "dried" refers to drying over anhydrous sodium sulfate, rt (RT) refers to room temperature, DMSO = dimethylsulfoxide; DMF = N,N'-dimethylformamide, DCM = dichloromethane, EtOH = ethanol, DCE = dichloroethane, DME = 1,2-dimethoxyethane, Cy,cHex = cyclohexane, TEA = triethylamine, DIPEA = N,N-diisopropylethylamine, Boc 2 O = di-tert-butyl dicarbonate; TFA = trifluoroacetic acid, Pd 2 (dba) 3 = tris(dibenzylideneacetone)dipalladium(0), EDC HCl = N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride, HOBt = 1-hydroxybenzotriazole hydrate, SCX cartridge = strong cation exchange cartridge.

[0183] Preparation 1: 2,4-Dichloro-6-(trifluoromethyl)pyrimidine (P1) [ka]

[0184] 6-(Trifluoromethyl)uracil (3 g, 16.66 mmol), SOCl 2 A mixture of 1 mL of hexane (8 mL) and DMF (1 mL) was stirred at 80° C. for 4 h and then cooled to 0° C. Hexane and crushed ice were added to the resulting mixture, followed by CO 2 NaHCO 3 was carefully added. The organic layer was separated, dried, and carefully concentrated under reduced pressure with a water bath temperature below 35° C. to give 2,4-dichloro-6-(trifluoromethyl)pyrimidine (P1, 3.2 g, y=88%) as a pale yellow oil, which was used in the next step without further purification. [Table 1]

[0185] Preparation 2: 2-Chloro-4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidine (P2) [ka]

[0186] 2,4-Dichloro-6-(trifluoromethyl)pyrimidine (P1, 2 g, 9.2 mmol), 3-fluorophenol (0.75 mL, 8.2 mmol), and K 2 CO 3 A mixture of (1.66 g, 12 mmol) was heated at 60° C. for 20 min. After cooling at room temperature, EtOAc and water were added and the phases were separated. The organic phase was dried, evaporated and the crude material was purified by FC on silica gel (eluent: Cy to Cy / AcOEt 9 / 1) to give 2-chloro-4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidine (P2, 2.26 g, y=94%) as a pale yellow oil. [Table 2]

[0187] Preparation 3: 1-Bromo-3-fluoro-5-(3-fluorophenoxy)benzene (P3) [ka]

[0188] 3-Fluorophenol (0.178 mL, 1.97 mmol) and KOH (110 mg, 1.97 mmol) were stirred at 50° C. for 30 min, then 1,3-dibromo-5-fluorobenzene (500 mg, 1.97 mmol) and Cu powder (125 mg, 1.97 mmol) were added. The reaction mixture was heated to 150° C. for 2 h and then at 100° C. overnight. The crude product was purified by FC on silica gel (eluent: Cy) to give 1-bromo-3-fluoro-5-(3-fluorophenoxy)benzene (P3, 834 mg, y=22%) as an oil. [Table 3]

[0189] Preparation 4: Mixture of 1-bromo-2,3-difluoro-5-(3-fluorophenoxy)benzene and 5-bromo-1,2-difluoro-3-(3-fluorophenoxy)benzene (P4) [ka]

[0190] 3-Fluorophenol (0.117 mL, 1.29 mmol) and KOH (73 mg, 1.29 mmol) were stirred at 50° C. for 30 min, after which 1,5-dibromo-2,3-difluorobenzene (350 mg, 1.29 mmol) and Cu powder (82 mg, 1.29 mmol) were added. The reaction mixture was heated to 150° C. for 2 h and then at 100° C. overnight. The crude material was purified by FC on silica gel (eluent: Cy) to give a mixture of 1-bromo-2,3-difluoro-5-(3-fluorophenoxy)benzene and 5-bromo-1,2-difluoro-3-(3-fluorophenoxy)benzene (P4, 68 mg, y=17%) in ca. 1:1 ratio as an oil. [Table 4]

[0191] Preparation 5: 1-Bromo-2,5-difluoro-3-(3-fluorophenoxy)benzene (P5) [ka]

[0192] 3-Fluorophenol (0.099 mL, 1.1 mmol) and KOH (62 mg, 1.1 mmol) were stirred at 50° C. for 30 min, then 1,3-dibromo-2,5-difluorobenzene (300 mg, 1.1 mmol) and Cu powder (70 mg, 1.1 mmol) were added. The reaction mixture was heated at 100° C. overnight. The crude material was purified by FC on silica gel (eluent: Cy) to give 1-bromo-2,5-difluoro-3-(3-fluorophenoxy)benzene (P5, 61 mg, y=18%) as an oil. [Table 5]

[0193] Preparation 6: 1-Bromo-2-fluoro-3-phenoxybenzene (P6) [ka]

[0194] Method A: TEA (2.66 mL, 19.1 mmol) was dissolved in 3-bromo-2-fluorophenol (730 mg, 3.82 mmol), phenylboronic acid (932 mg, 7.64 mmol), Cu(OAc) 2 (1.04 mg, 5.73 mmol), molecular sieves, and DCM (35 mL) were added to a mixture. The mixture was stirred at room temperature overnight, filtered through a pad of Celite and washed with DCM. The filtrate was concentrated and the crude material was purified by FC on silica gel (eluent: Cy) to give 1-bromo-2-fluoro-3-phenoxybenzene (P6, 40 mg, y=4%) as a colorless oil.

[0195] Method B: Step a 3-Chloroperbenzoic acid (640 mg, 3 mmol) was dissolved in DCM (10 mL). Iodobenzene (0.31 mL, 2.7 mmol) was added to the solution, which was then cooled to room temperature with BF 3 OEt 2(0.850 mL, 6.8 mmol) was slowly added. The resulting yellow solution was stirred at room temperature for 30 min, cooled to 0° C., and then phenylboronic acid (370 mg, 3 mmol) was added in one portion. After 15 min at room temperature, the crude reaction mixture was loaded onto a silica cartridge (6 g) and eluted with DCM (60 mL) followed by DCM / MeOH 20 / 1 (120 mL). The latter solution was concentrated and diluted with Et 2 Add O and Et 2 The product was precipitated by further trituration with O. After decantation, the off-white solid was dried to give diphenyliodonium tetrafluoroborate (1 g).

[0196] Step B To a suspension of t-BuOK (43 mg, 0.37 mmol) in THF (1.5 mL) was added 3-bromo-2-fluorophenol (65 mg, 0.34 mmol) at 0° C. and the reaction mixture was left stirring for 15 min. Diphenyliodonium tetrafluoroborate (from step a, 145 mg, 0.4 mmol) was added in one portion and the reaction was stirred at 40° C. for 1 h. The reaction was then cooled to 5° C. for 1 h. 2 The mixture was quenched with O and the product was extracted with DCM. The organic phase was evaporated and the crude material was purified by FC on silica gel (eluent: pentane) to give 1-bromo-2-fluoro-3-phenoxybenzene (P6, 69 mg, y=76%). [Table 6]

[0197] Preparation 7: 1-Bromo-2-fluoro-3-(3-fluorophenoxy)benzene (P7) [ka]

[0198] Method A 3-Fluorophenol (0.107 mL, 1.18 mmol) and KOH (66 mg, 1.18 mmol) were stirred at 50° C. for 30 min, then 1,3-dibromo-2-fluorobenzene (300 mg, 1.18 mmol) and Cu powder (75 mg, 1.18 mmol) were added. The reaction mixture was heated at 100° C. overnight. The crude material was purified by FC on silica gel (eluent: Cy) to give 1-bromo-2-fluoro-3-(3-fluorophenoxy)benzene (P7, 12 mg, y=3.5%) as an oil.

[0199] Method B Step a 3-Chloroperbenzoic acid (640 mg, 3 mmol) was dissolved in DCM (10 mL). 3-Fluoro-iodobenzene (0.317 mL, 2.7 mmol) was added to the solution, followed by addition of BF at room temperature. 3 OEt 2 (0.850 mL, 6.8 mmol) was slowly added. The resulting yellow solution was stirred at room temperature for 30 min, then cooled at 0° C. and 3-fluoro-phenylboronic acid (420 mg, 3 mmol) was added in one portion. After 15 min at room temperature, the crude reaction mixture was loaded onto a silica cartridge (6 g) and eluted with DCM (60 mL) followed by DCM / MeOH 20 / 1 (120 mL). The latter solution was concentrated and diluted with Et 2 O was added to triturate the product. After decantation, the pale yellow solid was dried to give bis(3-fluoro-phenyl)iodonium tetrafluoroborate (820 mg).

[0200] Step B To a suspension of t-BuOK (97 mg, 1.1 eq) in THF (3.5 mL) was added 3-bromo-2-fluorophenol (150 mg, 0.785 mmol) at 0° C. and the reaction was left stirring at that temperature for 15 min. Bis(3-fluoro-phenyl)iodonium tetrafluoroborate (from step a, 381 mg, 0.942 mmol) was added in one portion and the reaction was stirred at 40° C. for 1 h. The reaction was then cooled to 5° C. for 1 h. 2The mixture was quenched with O and the product was extracted with DCM. The organic phase was evaporated and the crude material was purified by FC on silica gel (eluent: pentane) to give 1-bromo-2-fluoro-3-(3-fluorophenoxy)benzene (P7, 160 mg, y=71%). [Table 7]

[0201] Preparation 8: 6-Benzyl-1-oxa-6-azaspiro[2.5]octane (P8) [ka]

[0202] To an ice-cooled mixture of NaH (60% dispersion in mineral oil, 2.75 g, 68.69 mmol) and trimethylsulfoxonium iodide (12.79 g, 58.12 mmol) was added DMSO (50 mL) while keeping the mixture at 10° C. After stirring the mixture at 10° C. for 10 min, it was allowed to reach room temperature and left at that temperature with stirring for 1 h. A solution of 1-benzylpiperidin-4-one (9.79 mL, 52.84 mmol) in DMSO (30 mL) was added via syringe. The mixture was stirred at room temperature for 1.5 h and then diluted with Et 2 Dilute with NH 4 The reaction was quenched by the addition of saturated aqueous Cl. The phases were separated and the aqueous phase was diluted with Et 2 Back-extracted with O. The combined organics were dried, filtered and concentrated under reduced pressure to give 6-benzyl-1-oxa-6-azaspiro[2.5]octane (P8, 11.3 g, y=quantitative) as crude material which was used directly in the next step. [Table 8]

[0203] Preparation 9: 1-Benzyl-4-[(dimethylamino)methyl]piperidin-4-ol (P9) [ka]

[0204] To a stirred solution of 6-benzyl-1-oxa-6-azaspiro[2.5]octane (P8, 0.5 g, 2.46 mmol) in MeOH / water (2 / 4 mL) was added dropwise dimethylamine 40% in water (0.62 mL, 4.92 mmol) at 0° C. Once the addition was complete, the ice bath was removed and the resulting reaction mixture was stirred at room temperature for 2 h. The solvent was removed under reduced pressure and the residue was partitioned between DCM and a 1 M aqueous solution of NaOH. The organic phase was dried and concentrated under reduced pressure to give 1-benzyl-4-[(dimethylamino)methyl]piperidin-4-ol (P9, 612 mg, y=quantitative), which was used as such in the next step. [Table 9]

[0205] Example 1: 4-[(Dimethylamino)methyl]-1-[4-(3-fluorophenoxy)-6(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E1) [ka]

[0206] Step a To a solution of 1-benzyl-4-[(dimethylamino)methyl]piperidin-4-ol (P9, 200 mg, 0.8 mmol) in MeOH (5 mL) was added ammonium formate (305 mg, 4.83 mmol) and 10% Pd / C (12 mg) at room temperature, then the mixture was stirred at reflux for 1 h. The mixture was cooled to room temperature, filtered through a pad of Celite, and washed with MeOH. The solvent was removed under reduced pressure to give 4-[(dimethylamino)methyl]piperidin-4-ol (259 mg) as the formate salt, which was used as such in the next step.

[0207] Step B To a solution of 4-[(dimethylamino)methyl]piperidin-4-ol (from step a, 75 mg, 0.22 mmol) in DMSO (2 mL) was added 2-chloro-4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidine (P2, 66 mg, 0.22 mmol) and K 2 CO 3 (92 mg, 0.66 mmol) was added at room temperature, then the mixture was shaken at 50° C. for 1 h. The mixture was cooled, diluted with AcOEt and washed with water. The organic phase was dried, concentrated and the crude material was purified by FC on silica gel (eluent: DCM to DCM / MeOH 8:2) and then further purified by FC on NH column (eluent: Cy to Cy / AcOEt 7:3) to give 4-[(dimethylamino)methyl]-1-[4-(3-fluorophenoxy)-6(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E1, 28 mg). [Table 10]

[0208] Preparation 10: 1-Benzyl-4-(pyrrolidin-1-ylmethyl)piperidin-4-ol (P10) [ka]

[0209] To a stirred solution of 6-benzyl-1-oxa-6-azaspiro[2.5]octane (P8, 0.2 g, 0.98 mmol) in MeOH / water (1 / 2 mL) was added pyrrolidine (0.164 mL, 1.96 mmol) dropwise. Upon complete addition, the resulting reaction mixture was shaken at room temperature for 2 h. The solvent was removed under reduced pressure and the residue was partitioned between DCM and a 1M aqueous solution of NaOH. The organic phase was dried and concentrated under reduced pressure to give 1-benzyl-4-(pyrrolidin-1-ylmethyl)piperidin-4-ol (P10, 280 mg, y=quantitative), which was used directly in the next step. [Table 11]

[0210] Example 2: 1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-(pyrrolidin-1-ylmethyl)piperidin-4-ol (E2) [ka]

[0211] Step A: To a solution of 1-benzyl-4-(pyrrolidin-1-ylmethyl)piperidin-4-ol (P10, 280 mg, 1.02 mmol) in MeOH (5 mL) was added ammonium formate (386 mg, 6.12 mmol) and 10% Pd / C (30 mg) at room temperature, then the mixture was stirred at reflux for 1 h. The mixture was cooled to room temperature and filtered through a pad of Celite, washing with MeOH. The solvent was removed under reduced pressure to give 4-(pyrrolidin-1-ylmethyl)piperidin-4-ol (280 mg).

[0212] Step B: To a solution of 1-benzyl-4-(pyrrolidin-1-ylmethyl)piperidin-4-ol (from step a, 80 mg, 0.43 mmol) in DMSO (2 mL) was added 2-chloro-4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidine (P2, 102 mg, 0.35 mmol) and K 2 CO 3 (178 mg, 1.29 mmol) was added at room temperature and then the mixture was shaken at 60° C. for 2 h. The mixture was cooled, diluted with DCM and washed with water. The organic phase was dried, concentrated and the crude material was purified by FC on an NH column (eluent: Cy to Cy / AcOEt 1:1) to give 1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-(pyrrolidin-1-ylmethyl)piperidin-4-ol (E2, 42 mg, y=22%) [Table 12]

[0213] Preparation 11: 1-Benzyl-4-[(cyclopropylamino)methyl]piperidin-4-ol (P11) [ka]

[0214] To a stirred solution of 6-benzyl-1-oxa-6-azaspiro[2.5]octane (P8, 0.2 g, 0.98 mmol) in MeOH / water (1 / 2 mL) was added cyclopropylamine (0.136 mL, 1.97 mmol) dropwise at 0° C. Upon complete addition, the ice bath was removed and the resulting reaction mixture was stirred at room temperature for 2 h. The solvent was removed under reduced pressure and the residue was partitioned between DCM and a 1M aqueous solution of NaOH. The organic phase was dried and concentrated under reduced pressure to give 1-benzyl-4-[(cyclopropylamino)methyl]piperidin-4-ol (P11, 260 mg, y=quantitative), which was used directly in the next step. [Table 13]

[0215] Preparation 12: tert-Butyl N-[(1-benzyl-4-hydroxypiperidin-4-yl)methyl]-N-cyclopropylcarbamate (P12) [ka]

[0216] To a solution of 1-benzyl-4-[(cyclopropylamino)methyl]piperidin-4-ol (P8, 260 mg, 1 mmol) in 5 mL of DCM was added Boc 2 O (218 mg, 1 mmol) was added and the mixture was stirred at room temperature for 2 h, then the solvent was removed under reduced pressure to give tert-butyl N-[(1-benzyl-4-hydroxypiperidin-4-yl)methyl]-N-cyclopropylcarbamate (P12, 391 mg, crude material), which was used as is. [Table 14]

[0217] Preparation 13: tert-Butyl N-cyclopropyl-N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P13) [ka]

[0218] Step A: To a solution of tert-butyl N-[(1-benzyl-4-hydroxypiperidin-4-yl)methyl]-N-cyclopropylcarbamate (P12, 391 mg, 1.08 mmol) in MeOH (5 mL) was added ammonium formate (408 mg, 6.48 mmol) and 10% Pd / C (30 mg) at room temperature, and the mixture was then stirred at reflux for 3 h. After that, the mixture was cooled to room temperature and filtered through a pad of Celite, washing with MeOH. The solvent was removed under reduced pressure to give tert-butyl N-cyclopropyl-N-[(4-hydroxypiperidin-4-yl)methyl]carbamate (425 mg).

[0219] Step B: 2-Chloro-4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidine (P2, 65 mg, 0.222 mmol), tert-butyl N-cyclopropyl-N-[(4-hydroxypiperidin-4-yl)methyl]carbamate (from step a, 100 mg, 0.222 mmol), and K 2 CO 3(40 mg, 0.289 mmol) were mixed in dry DMSO (1 mL) and the mixture was shaken at 60° C. for 1 h. The mixture was then diluted with EtOAC and water. The organic phase was washed several times with brine, dried, filtered and evaporated. The crude material was purified by FC on a NH column (eluent: Cy to Cy90 / EtOAc10) to give tert-butyl N-cyclopropyl-N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P13, 50 mg). [Table 15]

[0220] Example 3: 4-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E3) [ka]

[0221] TFA (0.5 mL) was added to a solution of tert-butyl N-cyclopropyl-N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P13, 50 mg, 0.095 mmol) in 3 mL of DCM. The mixture was stirred at room temperature for 1 h, then the solvent was removed under reduced pressure. The residue was loaded onto an SCX cartridge, washed with MeOH, and purified with 1M NH in MeOH. 3 to give 4-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E3, 40 mg, y=98%). [Table 16]

[0222] Example: 4-{[cyclopropyl(methyl)amino]methyl}-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E4) [ka]

[0223] To a solution of 4-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E3, 20 mg, 0.047 mmol) in DCM (2 mL) was added formaldehyde (0.035 mL, 0.47 mmol) and the mixture was stirred at room temperature for 15 min. 3 (38 mg, 0.180 mmol) was added and the mixture was stirred at room temperature overnight. Water was added and the phases were separated. The organic phase was washed with brine, dried, filtered and evaporated to give 4-{[cyclopropyl(methyl)amino]methyl}-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E4, 15 mg, y=72%). [Table 17]

[0224] Preparation 14: 1-Benzyl-4-[(methylamino)methyl]piperidin-4-ol (P14) [ka]

[0225] To a stirred solution of 6-benzyl-1-oxa-6-azaspiro[2.5]octane (P8, 0.2 g, 0.98 mmol) in MeOH / water (1 / 2 mL) was added dropwise methylamine 33% in ethanol (0.244 mL, 1.97 mmol) at 0° C. Once the addition was complete, the ice bath was removed and the resulting reaction mixture was stirred at room temperature for 2 h. The solvent was removed under reduced pressure and the residue was partitioned between DCM and a 1 M aqueous solution of NaOH. The organic phase was dried and concentrated under reduced pressure to give 1-benzyl-4-[(methylamino)methyl]piperidin-4-ol (P14, 222 mg, y=97%), which was used as such in the next step. [Table 18]

[0226] Preparation 15: tert-Butyl N-[(1-benzyl-4-hydroxypiperidin-4-yl)methyl]-N-methylcarbamate (P15) [ka]

[0227] 1-Benzyl-4-[(methylamino)methyl]piperidin-4-ol (P14, 220 mg, 0.939 mmol) was dissolved in DCM (2 mL) and TEA (0.2 mL, 1.41 mmol) was added, followed by Boc 2 A solution of NH 2 O (247 mg, 1.13 mmol) was added. The resulting solution was stirred at room temperature for 2 h. 4 Cl was added, the organic phase was separated, dried and concentrated. The crude material was purified by FC on silica gel (eluent: EtOAc to EtOAc / MeOH 90 / 10) to give tert-butyl N-[(1-benzyl-4-hydroxypiperidin-4-yl)methyl]-N-methylcarbamate (P15, 240 mg, y=76%) as a colorless oil. [Table 19]

[0228] Preparation 16: tert-Butyl N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-N-methylcarbamate (P16) [ka]

[0229] Step A: To a solution of tert-butyl N-[(1-benzyl-4-hydroxypiperidin-4-yl)methyl]-N-methylcarbamate (P15, 240 mg, 0.718 mmol) in MeOH (6 mL) was added ammonium formate (272 mg, 4.31 mmol) and 10% Pd / C (72 mg) at room temperature, and the mixture was then stirred at reflux for 1 h. After that, the mixture was cooled to room temperature and filtered through a pad of Celite, washing with MeOH. The solvent was removed under reduced pressure to give tert-butyl N-[(4-hydroxypiperidin-4-yl)methyl]-N-methylcarbamate (150 mg) as a colorless oil.

[0230] Step B: 2-Chloro-4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidine (P2, 60 mg, 0.205 mmol), tert-butyl N-[(4-hydroxypiperidin-4-yl)methyl]-N-methylcarbamate (from step a, 50 mg, 0.205 mmol), and K 2 CO 3 (37 mg, 0.267 mmol) were mixed in dry DMSO (1 mL) and the mixture was shaken at 60° C. for 1 h. The mixture was diluted with EtOAC and water. The organic phase was washed several times with brine, dried, filtered, evaporated and the crude material was purified by FC on an NH column (eluent: Cy to Cy85 / EtOAc15) to give tert-butyl N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-N-methylcarbamate (P16, 40 mg). [Table 20]

[0231] Example 5: 1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-[(methylamino)methyl]piperidin-4-ol (E5) [ka]

[0232] TFA (0.5 mL) was added to a solution of N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-tert-butyl N-methylcarbamate (P16, 40 mg, 0.080 mmol) in DCM (3 mL). The mixture was stirred at room temperature for 1 h, then the solvent was removed under reduced pressure. The residue was loaded onto an SCX cartridge, washed with MeOH and purified with 1M NH in MeOH. 3 to give 1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-[(methylamino)methyl]piperidin-4-ol (E5, 30 mg, y=94%). [Table 21]

[0233] Preparation 17: 1-Benzyl-4-[(3,3-difluoropyrrolidin-1-yl)methyl]piperidin-4-ol (P17) [ka]

[0234] To a stirred solution of 6-benzyl-1-oxa-6-azaspiro[2.5]octane (P8, 0.2 g, 0.98 mmol) in MeOH (1 mL) was added H 2A solution of 3,3-difluoropyrrolidine hydrochloride (282 mg, 1.96 mmol) and TEA (0.272 mL, 1.96 mmol) in 2 mL of O was added dropwise. Upon complete addition, the resulting reaction mixture was shaken overnight at room temperature. The solvent was removed under reduced pressure and the residue was partitioned between DCM and a 1M aqueous solution of NaOH. The organic phase was dried and concentrated under reduced pressure to give 1-benzyl-4-[(3,3-difluoropyrrolidin-1-yl)methyl]piperidin-4-ol (P17, 305 mg, y=quantitative), which was used directly in the next step. [Table 22]

[0235] Example 6: 4-[(3,3-difluoropyrrolidin-1-yl)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E6) [ka]

[0236] Step A: To a solution of 1-benzyl-4-[(3,3-difluoropyrrolidin-1-yl)methyl]piperidin-4-ol (P17, 305 mg, 0.98 mmol) in MeOH (8 mL) was added ammonium formate (370 mg, 5.88 mmol) and 10% Pd / C (30 mg) at room temperature, and the mixture was then stirred at reflux for 3 h. The mixture was then cooled to room temperature and filtered through a pad of Celite, washing with MeOH. The solvent was removed under reduced pressure to give 4-[(3,3-difluoropyrrolidin-1-yl)methyl]piperidin-4-ol (320 mg).

[0237] Step B: 4-[(3,3-difluoropyrrolidin-1-yl)methyl]piperidin-4-ol (from step a, 80 mg, 0.195 mmol), 2-chloro-4-(3-fluorophenoxy)-6(trifluoromethyl)pyrimidine (P2, 44 mg, 0.195 mmol), and K 2 CO 3 (35 mg, 0.253 mmol) was heated at 100° C. for 1 h. After cooling to room temperature, EtOAc and water were added and the phases were separated. The organic phase was dried, evaporated and the residue was purified by FC on a NH column (eluent: cHex to cHex80 / EtOAc20) to give 4-[(3,3-difluoropyrrolidin-1-yl)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E6, 27 mg) as a colorless oil. [Table 23]

[0238] Preparation 18: tert-Butyl 4-[(1-benzyl-4-hydroxypiperidin-4-yl)methyl]-1,4-diazepane-1-carboxylate (P18) [ka]

[0239] To a stirred mixture of 6-benzyl-1-oxa-6-azaspiro[2.5]octane (P8, 300 mg, 1.48 mmol) in MeOH (1.5 mL) and water (2 mL) was added a solution of tert-butyl 1,4-diazepane-1-carboxylate (0.58 mL, 2.95 mmol) in MeOH (0.5 mL) and the resulting reaction mixture was shaken overnight at room temperature. The mixture was concentrated under reduced pressure, the residue was taken up with DCM and saturated sodium bicarbonate, the organic phase was washed with water, dried under vacuum and concentrated. The residue was purified by FC on silica gel (eluent: DCM to DCM / MeOH 97 / 3) to give tert-butyl 4-[(1-benzyl-4-hydroxypiperidin-4-yl)methyl]-1,4-diazepane-1-carboxylate (P18, 367 mg, y=66%) as a colorless oil. [Table 24]

[0240] Preparation 19: tert-Butyl 4-[(4-hydroxypiperidin-4-yl)methyl]-1,4-diazepane-1-carboxylate (P19) [ka]

[0241] To a solution of tert-butyl 4-[(1-benzyl-4-hydroxypiperidin-4-yl)methyl]-1,4-diazepane-1-carboxylate (P18, 367 mg, 0.91 mmol) in MeOH (20 mL) was added ammonium formate (344 mg, 5.46 mmol) and 10% Pd / C (114 mg) at room temperature, then the mixture was stirred at reflux. After 2 h, the reaction mixture was filtered through a pad of Celite and the solvent was removed under vacuum. The residue was dissolved in DCM and the organic solution was washed with saturated NaHCO 3 After washing with ethyl acetate, the extract was dried and concentrated under reduced pressure to give tert-butyl 4-[(4-hydroxypiperidin-4-yl)methyl]-1,4-diazepane-1-carboxylate (P19, 139 mg, y=49%) as a colorless oil. [Table 25]

[0242] Preparation 19A: tert-Butyl 4-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-1,4-diazepane-1-carboxylate (P19A) [ka]

[0243] In a sealed vessel, tert-butyl 4-[(4-hydroxypiperidin-4-yl)methyl]-1,4-diazepane-1-carboxylate (P19, 64 mg, 0.21 mmol), 2-chloro-4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidine (P2, 60 mg, 0.21 mmol), and K were added in DMSO (0.8 mL). 2 CO 3 A mixture of (38 mg, 0.27 mmol) was heated at 90° C. and shaken at this temperature for 2 h. After cooling at room temperature, EA and water were added and the organic phase was washed with water, dried and evaporated. The crude product was purified by FC on an NH column (eluent: Cy to Cy / EA 80 / 20) to give tert-butyl 4-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-1,4-diazepane-1-carboxylate (P19A, 73 mg, y=61%). [Table 26]

[0244] Example 7: 4-(1,4-diazepan-1-ylmethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol hydrochloride (E7) [ka]

[0245] Step a To a solution of tert-butyl 4-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-1,4-diazepane-1-carboxylate (P19A, 73 mg, 0.13 mmol) in DCM (0.6 mL) was added TFA (0.29 mL) at room temperature. After 2 h, the reaction mixture was concentrated in vacuum. The residue was taken up with DCM and concentrated sodium bicarbonate, the organic phase was dried and the solvent was removed in vacuum to give 4-(1,4-diazepan-1-ylmethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (35 mg).

[0246] Step B 4-(1,4-diazepan-1-ylmethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (from step a, 35 mg, 0.075 mmol) was dissolved in DCM (0.2 mL) and 2N HCl in ether (0.037 mL) was added. The mixture was concentrated under reduced pressure and the residue was triturated with ether and dried under vacuum to give 4-(1,4-diazepan-1-ylmethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol hydrochloride (E8, 11 mg, y=17%). [Table 27]

[0247] Preparation 20: 1-Benzyl-4-[(2,5-dimethylpyrrolidin-1-yl)methyl]piperidin-4-ol (P20) [ka]

[0248] To a stirred solution of 6-benzyl-1-oxa-6-azaspiro[2.5]octane (P8, 0.2 g, 0.98 mmol) in MeOH / water (2 / 4 mL) was added 2,5-dimethylpyrrolidine (0.241 mL, 1.97 mmol) dropwise. Upon complete addition, the reaction mixture was shaken at room temperature for 2 h and then at 45° C. overnight. The solvent was removed under reduced pressure and the residue was partitioned between DCM and a 1 M aqueous solution of NaOH. The organic phase was dried and concentrated under reduced pressure to give 1-benzyl-4-[(2,5-dimethylpyrrolidin-1-yl)methyl]piperidin-4-ol (P20, 263 mg, y=88%), which was used as such in the next step. [Table 28]

[0249] Preparation 21: 4-[(2,5-dimethylpyrrolidin-1-yl)methyl]piperidin-4-ol (P21) [ka]

[0250] To a solution of 1-benzyl-4-[(2,5-dimethylpyrrolidin-1-yl)methyl]piperidin-4-ol (P20, 263 mg, 0.87 mmol) in MeOH (5 mL) was added ammonium formate (0.329 g, 5.21 mmol) and 10% Pd / C (20 mg) at room temperature, and the mixture was then stirred at reflux for 1.5 h. The mixture was then cooled to room temperature and filtered through a pad of Celite, washing with MeOH. The solvent was removed under reduced pressure to give 4-[(2,5-dimethylpyrrolidin-1-yl)methyl]piperidin-4-ol (P21, 340 mg, crude material). [Table 29]

[0251] Example 8: 4-[(2,5-dimethylpyrrolidin-1-yl)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E8) [ka]

[0252] A solution of 4-[(2,5-dimethylpyrrolidin-1-yl)methyl]piperidin-4-ol (P21, 50 mg, 0.24 mmol) in DMSO (2 mL) was treated with 2-chloro-4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidine (69 mg, 0.24 mmol) and K 2 CO 3 (66 mg, 0.48 mmol) was added at room temperature and the mixture was then shaken at 50° C. for 2 h. The mixture was cooled to room temperature, diluted with DCM and washed with water. The organic phase was dried and concentrated and the crude material was purified by FC on silica gel (eluent: Cy to Cy / AcOEt 1 / 1) then loaded onto an SCX cartridge, washed with MeOH and diluted with 1M NH in MeOH. 3 to give 4-[(2,5-dimethylpyrrolidin-1-yl)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E8, 20 mg, y=18%). [Table 30]

[0253] Preparation 22: 1-Benzyl-4-[(tert-butylamino)methyl]piperidin-4-ol (P22) [ka]

[0254] To a stirred solution of 6-benzyl-1-oxa-6-azaspiro[2.5]octane (P8, 0.2 g, 0.98 mmol) in MeOH / water (1 / 2 mL) was added tert-butylamine (0.2 mL, 1.97 mmol) dropwise at 0° C. Upon complete addition, the ice bath was removed and the resulting reaction mixture was stirred at 45° C. overnight. The solvent was removed under reduced pressure and the residue was partitioned between DCM and a 1M aqueous solution of NaOH. The organic phase was dried and concentrated under reduced pressure to give 1-benzyl-4-[(tert-butylamino)methyl]piperidin-4-ol (P22, 270 mg, y=quantitative), which was used directly in the next step. [Table 31]

[0255] Preparation 23: 4-[(tert-butylamino)methyl]piperidin-4-ol (P23) [ka]

[0256] To a solution of 1-benzyl-4-[(tert-butylamino)methyl]piperidin-4-ol (P22, 270 mg, 0.98 mmol) in MeOH (8 mL) was added ammonium formate (370 mg, 5.88 mmol) and 10% Pd / C (90 mg) at room temperature, then the mixture was stirred at reflux for 1 h. The mixture was cooled to room temperature, filtered through a pad of Celite, and washed with MeOH. The solvent was removed under reduced pressure to give 4-[(tert-butylamino)methyl]piperidin-4-ol (P23, 180 mg, y=quantitative) as a white solid. [Table 32]

[0257] Example 9: 4-[(tert-butylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E9) [ka]

[0258] 2-Chloro-4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidine (P2, 73 mg, 0.249 mmol), 4-[(tert-butylamino)methyl]piperidin-4-ol (P23, 50 mg, 0.268 mmol), and K 2 CO 3 (44 mg, 0.323 mmol) was heated at 45° C. for 1 h. After cooling to room temperature, EtOAc and water were added and the product was extracted into the organic phase. The organic phase was dried, evaporated and the residue was purified by FC on a NH column (eluent: cHex to cHex / EtOAc 80 / 20) to give 4-[(tert-butylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E9, 59 mg, y=53%) as a yellowish oil. [Table 33]

[0259] Preparation 24: 1-[(1-benzyl-4-hydroxypiperidin-4-yl)methyl]pyrrolidin-2-one (P24) [ka]

[0260] To a mixture of pyrrolidin-2-one (250 mg, 2.94 mmol) in DMF (10 mL) was added at 0° C. a 60% dispersion of NaH in mineral oil (125 mg, 3.2 mmol), the suspension was stirred at 0° C. for 30 min, then a solution of 6-benzyl-1-oxa-6-azaspiro[2.5]octane (P8, 200 mg, 0.98 mmol) in DMF (2 mL) was added. The mixture was allowed to reach room temperature and stirred at that temperature for 1.5 h. The mixture was then heated to 80° C. and stirred at that temperature for an additional 2 h. The reaction mixture was cooled to room temperature, poured into water / ice and extracted twice with AcOEt. The organic phase was dried under reduced pressure, concentrated and the residue containing DMF was loaded onto an SCX cartridge, washed with MeOH and eluted with 1M NH in MeOH. 3 The solvent was removed under reduced pressure to give 1-[(1-benzyl-4-hydroxypiperidin-4-yl)methyl]pyrrolidin-2-one (P24, 128 mg, y=45%). [Table 34]

[0261] Preparation 25: 1-[(4-hydroxypiperidin-4-yl)methyl]pyrrolidin-2-one (P25) [ka]

[0262] To a solution of 1-[(1-benzyl-4-hydroxypiperidin-4-yl)methyl]pyrrolidin-2-one (P24, 128 mg, 0.44 mmol) in MeOH (5 mL) was added ammonium formate (0.168 g, 2.66 mmol) and 10% Pd / C (15 mg) at room temperature, then the mixture was stirred at reflux for 1.5 h. The mixture was cooled to room temperature, filtered through a pad of Celite, and washed with MeOH. The solvent was removed under reduced pressure to give 1-[(4-hydroxypiperidin-4-yl)methyl]pyrrolidin-2-one (P25, 85 mg, y=97%). [Table 35]

[0263] Example 10: 1-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)pyrrolidin-2-one (E10) [ka]

[0264] A solution of 1-[(4-hydroxypiperidin-4-yl)methyl]pyrrolidin-2-one (P25, 82 mg, 0.35 mmol) in DMSO (2 mL) was added to 2-chloro-4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidine (P2, 103 mg, 0.35 mmol) and K 2 CO 3 (97 mg, 0.7 mmol) was added at room temperature and the mixture was then shaken at 50° C. for 2 h. The mixture was cooled, diluted with DCM and washed with water. The organic phase was dried and concentrated and the crude material was purified by FC on silica gel (eluent: Cy to AcOEt) to give 1-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)pyrrolidin-2-one (E10, 85 mg, y=53%). [Table 36]

[0265] Preparation 26: 4-(aminomethyl)-1-benzylpiperidin-4-ol (P26) [ka]

[0266] To a stirred solution of 6-benzyl-1-oxa-6-azaspiro[2.5]octane (P8, 3 g, 14.7 mmol) in MeOH (18 mL) at 0 °C was added NH 4A 28% aqueous solution of OH (36 mL) was added. Once the addition was complete, the ice bath was removed and the resulting reaction mixture was stirred at room temperature overnight. The reaction mixture was then concentrated under reduced pressure, the residue was taken up with DCM and 1N NaOH, the aqueous phase was back extracted with DCM, and the combined organics were dried and concentrated under reduced pressure. 4-(aminomethyl)-1-benzylpiperidin-4-ol (P26, 2.9 g, y=89%) was obtained as a colorless oil. It was used as such in the next step. [Table 37]

[0267] Preparation 27: tert-Butyl N-[(1-benzyl-4-hydroxypiperidin-4-yl)methyl]carbamate (P27) [ka]

[0268] A solution of 4-(aminomethyl)-1-benzylpiperidin-4-ol (P26, 2.9 g, 13.18 mmol) in DCM (30 mL) was added to a solution of Boc 2 A solution of 1H2O (2.87 mg, 13.18 mmol) was added and the mixture was stirred at room temperature for 14 h. The solvent was removed under reduced pressure and the crude material was purified by FC on silica gel (eluent: Cy to AcOEt) to give tert-butyl N-[(1-benzyl-4-hydroxypiperidin-4-yl)methyl]carbamate (P27, 2.9 g, y=68.7%) as a white solid. [Table 38]

[0269] Preparation 28: tert-Butyl N-[(4-hydroxypiperidin-4-yl)methyl]carbamate (P28) [ka]

[0270] To a solution of tert-butyl N-[(1-benzyl-4-hydroxypiperidin-4-yl)methyl]carbamate (P27, 2.9 g, 9.06 mmol) in MeOH (50 mL) was added ammonium formate (3.42 g, 54.3 mmol) and 10% Pd / C (0.3 g) at room temperature, then the mixture was stirred at reflux for 1 h. The mixture was cooled to room temperature, filtered through a pad of Celite, and washed with MeOH. The solvent was removed under reduced pressure to give tert-butyl N-[(4-hydroxypiperidin-4-yl)methyl]carbamate (P28, 2.2 g, y = 90% quantitative by weight) as a clear oil. [Table 39]

[0271] Preparation 29: tert-Butyl N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P29) [ka]

[0272] To a solution of tert-butyl N-[(4-hydroxypiperidin-4-yl)methyl]carbamate (P28, 0.34 g, 1.36 mmol (90 wt%)) in DMSO (6 mL) was added 2-chloro-4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidine (P2, 0.4 g, 1.36 mmol) and K 2 CO 3(0.37 g, 2.72 mmol) was added at room temperature and then the mixture was shaken at 50° C. for 2 h. The mixture was cooled, diluted with DCM and washed with water. The organic phase was dried, concentrated and the crude material was purified by FC on silica gel (eluent: Cy to Cy / AcOEt 1:1) to give tert-butyl N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P29, 350 mg, y=53%) as a white solid. [Table 40]

[0273] Example 11: 4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E11) [ka]

[0274] TFA (0.5 mL) was added to a solution of tert-butyl N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P29, 150 mg, 0.308 mmol) in DCM (5 mL). The mixture was stirred at room temperature for 1 h, then the solvent was removed under reduced pressure. The residue was loaded onto an SCX cartridge, washed with MeOH and purified with 1M NH in MeOH. 3 to give 4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E11, 105 mg, y=88%). [Table 41]

[0275] Example 12: 4-(Aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol hydrochloride (E12) [ka]

[0276] 4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E11, 80 mg, 0.207 mmol) was dissolved in DCM (1 mL) and treated with 2 M HCl in diethyl ether (0.109 mL, 0.217 mmol). The solvent was then evaporated to give 4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol hydrochloride (E12, 88 mg, y=100%) as a white solid. [Table 42]

[0277] Preparation 30: tert-Butyl N-({4-fluoro-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl}methyl)carbamate (P30) [ka]

[0278] To a solution of tert-butyl N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P29, 51 mg, 0.109 mmol) in DCM (2 mL) at 0 °C was added diethylaminosulfur trifluoride (0.029 mL, 0.218 mmol) and the reaction mixture was cooled to 5°C with N 2 The mixture was stirred under reduced pressure for 1 hour at 0°C. 4Cl was added, the organic phase was separated, dried and the solvent was evaporated. The crude material was purified by FC on silica gel (eluent: Cy to Cy / AcOEt 1:1) to give tert-butyl N-({4-fluoro-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl}methyl)carbamate (P30, 28 mg, y=52%). [Table 43]

[0279] Example 13: {4-Fluoro-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl}methanamine (E13) [ka]

[0280] To a solution of tert-butyl N-({4-fluoro-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl}methyl)carbamate (P30, 28 mg, 0.057 mmol) in DCM (4 mL) was added 0.1 mL of TFA and the solution was stirred at room temperature for 1 h. The reaction mixture was diluted with DCM and diluted with NaHCO at 0 °C. 3 The organic phase was dried and concentrated under reduced pressure. The crude material was loaded onto an SCX cartridge, washed with MeOH and washed with 1M NH 3 to give {4-fluoro-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl}methanamine (E13, 15 mg, y=68%). [Table 44]

[0281] Preparation 31: tert-Butyl N-({1-[3-fluoro-5-(3-fluorophenoxy)phenyl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P31) [ka]

[0282] To a stirred solution of tert-butyl N-[(4-hydroxypiperidin-4-yl)methyl]carbamate (P28, 50 mg, 0.217 mmol) and 1-bromo-3-fluoro-5-(3-fluorophenoxy)benzene (P3, 62 mg, 0.21 mmol) in DME (2 mL) at room temperature was added DavePhos (8.5 mg, 0.0217 mmol), Pd 2 (dba) 3 (6 mg, 0.007 mmol), and K 3 PO 4 (92 mg, 0.434 mmol) was added and nitrogen was removed for 10 min. The reaction was then shaken at 110° C. overnight. The reaction mixture was partitioned between water and EtOAc, and the organic phase was separated, dried and concentrated under reduced pressure. The crude material was purified by FC on silica gel (eluent: Cy to Cy / AcOEt 70 / 30) to give tert-butyl N-({1-[3-fluoro-5-(3-fluorophenoxy)phenyl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P31, 37 mg, y=39%) as a yellow oil. [Table 45]

[0283] Example 14: 4-(aminomethyl)-1-[3-fluoro-5-(3-fluorophenoxy)phenyl]piperidin-4-ol (E14) [ka]

[0284] TFA (0.2 mL) was added to a solution of tert-butyl N-({1-[3-fluoro-5-(3-fluorophenoxy)phenyl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P31, 37 mg, 0.085 mmol) in DCM (3 mL). The mixture was stirred at room temperature for 1 h, then the solvent was removed under reduced pressure. The residue was loaded onto an SCX cartridge and eluted with 1M NH in MeOH. 3 Elution with 500 rpm gave 4-(aminomethyl)-1-[3-fluoro-5-(3-fluorophenoxy)phenyl]piperidin-4-ol (E14, 28 mg, y=98%) as a pale yellow oil. [Table 46]

[0285] Preparation 32: tert-Butyl N-({1-[2,5-difluoro-3-(3-fluorophenoxy)phenyl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P32) [ka]

[0286] To a stirred solution of tert-butyl N-[(4-hydroxypiperidin-4-yl)methyl]carbamate (P28, 50 mg, 0.217 mmol) and 1-bromo-2,5-difluoro-3-(3-fluorophenoxy)benzene (P5, 66 mg, 0.217 mmol) in DME (2 mL) at room temperature was added DavePhos (8.5 mg, 0.0217 mmol), Pd 2 (dba) 3 (6 mg, 0.007 mmol), and K 3 PO 4(92 mg, 0.434 mmol) was added and nitrogen was removed for 10 min. The reaction mixture was shaken at 110° C. overnight. The reaction mixture was partitioned between water and EtOAc, and the organic phase was separated, dried and concentrated under reduced pressure. The crude material was purified by FC on silica gel (eluent: Cy to Cy70 / AcOEt30) to give tert-butyl N-({1-[2,5-difluoro-3-(3-fluorophenoxy)phenyl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P32, 10 mg, y=10%) as a yellow oil. [Table 47]

[0287] Example 15: 4-(aminomethyl)-1-[2,5-difluoro-3-(3-fluorophenoxy)phenyl]piperidin-4-ol (E15) [ka]

[0288] TFA (0.3 mL) was added to a solution of tert-butyl N-({1-[2,5-difluoro-3-(3-fluorophenoxy)phenyl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P32, 10 mg, 0.022 mmol) in DCM (3 mL). The mixture was stirred at room temperature for 1 h, then the solvent was removed under reduced pressure. The residue was loaded onto an SCX cartridge and eluted with 1M NH in MeOH. 3 Elution with 500 rpm gave 4-(aminomethyl)-1-[2,5-difluoro-3-(3-fluorophenoxy)phenyl]piperidin-4-ol (E15, 7 mg, y=90%) as a colourless oil. [Table 48]

[0289] Preparation 33: tert-Butyl N-{[1-(2-fluoro-3-phenoxyphenyl)-4-hydroxypiperidin-4-yl]methyl}carbamate (P33) [ka]

[0290] To a stirred solution of tert-butyl N-[(4-hydroxypiperidin-4-yl)methyl]carbamate (P28, 50 mg, 0.217 mmol) and 1-bromo-2-fluoro-3-phenoxybenzene (P6, 58 mg, 0.217 mmol) in DME (2 mL) at room temperature was added DavePhos (8.5 mg, 0.0217 mmol), Pd 2 (dba) 3 (6 mg, 0.007 mmol), and K 3 PO 4 (92 mg, 0.434 mmol) was added and nitrogen was removed for 10 min. The reaction was then shaken at 110° C. overnight. The mixture was partitioned between water and EtOAc, and the organic phase was separated, dried and concentrated under reduced pressure. The crude material was purified by FC on silica gel (eluent: Cy to Cy70 / AcOEt30) to give tert-butyl N-{[1-(2-fluoro-3-phenoxyphenyl)-4-hydroxypiperidin-4-yl]methyl}carbamate (P33, 30 mg, y=33%) as a yellow oil. [Table 49]

[0291] Example 16: 4-(aminomethyl)-1-(2-fluoro-3-phenoxyphenyl)piperidin-4-ol (E16) [ka]

[0292] TFA (0.3 mL) was added to a solution of tert-butyl N-{[1-(2-fluoro-3-phenoxyphenyl)-4-hydroxypiperidin-4-yl]methyl}carbamate (P33, 30 mg, 0.72 mmol) in DCM (3 mL). The mixture was stirred at room temperature for 1 h, then the solvent was removed under reduced pressure. The residue was loaded onto an SCX cartridge and 1M NH in MeOH was added.3 Elution with 500 rpm gave 4-(aminomethyl)-1-(2-fluoro-3-phenoxyphenyl)piperidin-4-ol (E16, 18 mg, y=80%) as a colorless oil. [Table 50]

[0293] Preparation 34: tert-Butyl N-({1-[2-fluoro-3-(3-fluorophenoxy)phenyl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P34) [ka]

[0294] To a stirred solution of tert-butyl N-[(4-hydroxypiperidin-4-yl)methyl]carbamate (P28, 50 mg, 0.217 mmol) and 1-bromo-2-fluoro-3-(3-fluorophenoxy)benzene (P7, 62 mg, 0.217 mmol) in DME (2 mL) at room temperature was added DavePhos (8.5 mg, 0.0217 mmol), Pd 2 (dba) 3 (6 mg, 0.007 mmol), and K 3 PO 4 (92 mg, 0.434 mmol) was added and nitrogen was removed for 10 min. The reaction was then shaken at 110° C. overnight. The mixture was partitioned between water and EtOAc, and the organic phase was separated, dried and concentrated under reduced pressure. The crude material was purified by FC on silica gel (eluent: Cy to Cy65 / AcOEt35) to give tert-butyl N-({1-[2-fluoro-3-(3-fluorophenoxy)phenyl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P34, 30 mg, y=32%) as a yellow oil. [Table 51]

[0295] Example 17: 4-(aminomethyl)-1-[2-fluoro-3-(3-fluorophenoxy)phenyl]piperidin-4-ol (E17) [ka]

[0296] TFA (0.3 mL) was added to a solution of tert-butyl N-({1-[2-fluoro-3-(3-fluorophenoxy)phenyl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P34, 30 mg, 0.069 mmol) in DCM (3 mL). The mixture was stirred at room temperature for 1 h, then the solvent was removed under reduced pressure. The residue was loaded onto an SCX cartridge and eluted with 1M NH in MeOH. 3 Elution with 500 rpm gave 4-(aminomethyl)-1-[2-fluoro-3-(3-fluorophenoxy)phenyl]piperidin-4-ol (E17, 18 mg, y=78%) as a colourless oil. [Table 52]

[0297] Preparations 35 and 36: tert-Butyl N-({1-[2,3-difluoro-5-(3-fluorophenoxy)phenyl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P35) and tert-Butyl N-({1-[3,4-difluoro-5-(3-fluorophenoxy)phenyl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P36) [ka]

[0298] To a stirred solution of tert-butyl N-[(4-hydroxypiperidin-4-yl)methyl]carbamate (P28, 106 mg, 0.46 mmol) and a ca. 1:1 mixture of 1-bromo-2,3-difluoro-5-(3-fluorophenoxy)benzene and 5-bromo-1,2-difluoro-3-(3-fluorophenoxy)benzene (P4, 140 mg, 0.46 mmol) in DME (3 mL) was added DavePhos (18 mg, 0.046 mmol), Pd 2 (dba) 3 (13 mg, 0.014 mmol), and K 3 PO 4 (195 mg, 0.92 mmol) was added, then nitrogen was removed for 10 min, the mixture was heated to 100 ° C and stirred at that temperature overnight. The reaction mixture was partitioned between water and EtOAc, the organic phase was separated, dried and concentrated under reduced pressure. The crude material was purified by FC on silica gel (eluent: Cy to Cy / AcOEt 60 / 40) to give tert-butyl N- ({1- [2,3-difluoro-5- (3-fluorophenoxy) phenyl] -4-hydroxypiperidin-4-yl} methyl) carbamate (P35, 68 mg, y = 32%) as a yellow solid and tert-butyl N- ({1- [3,4-difluoro-5- (3-fluorophenoxy) phenyl] -4-hydroxypiperidin-4-yl} methyl) carbamate (P36, 56 mg, y = 26%) as a yellow oil. [Table 53]

[0299] Example 18: 4-(aminomethyl)-1-[2,3-difluoro-5-(3-fluorophenoxy)phenyl]piperidin-4-ol (E18) [ka]

[0300] TFA (0.5 mL) was added to a solution of tert-butyl N-({1-[2,3-difluoro-5-(3-fluorophenoxy)phenyl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P35, 68 mg, 0.15 mmol) in DCM (3 mL) and the resulting mixture was stirred at room temperature for 1 h. The solvent was removed under vacuum and the residue was loaded onto an SCX cartridge and eluted with MeOH and 1M NH3 in MeOH. After evaporation, 4-(aminomethyl)-1-[2,3-difluoro-5-(3-fluorophenoxy)phenyl]piperidin-4-ol (E18, 50 mg, y=94%) was obtained as a yellow oil. [Table 54]

[0301] Example 19: 4-(aminomethyl)-1-[3,4-difluoro-5-(3-fluorophenoxy)phenyl]piperidin-4-ol (E19) [ka]

[0302] TFA (0.5 mL) was added to a solution of tert-butyl N-({1-[3,4-difluoro-5-(3-fluorophenoxy)phenyl]-4-hydroxypiperidin-4-yl}methyl)carbamate (P44, 56 mg, 0.15 mmol) in DCM (3 mL) and the resulting mixture was stirred at room temperature for 1 h. The solvent was removed in vacuo and the residue was loaded onto an SCX cartridge and eluted with MeOH and 1M NH in MeOH. 3 After evaporation, 4-(aminomethyl)-1-[3,4-difluoro-5-(3-fluorophenoxy)phenyl]piperidin-4-ol (E19, 44 mg, y=quantitative) was obtained as a yellow oil. [Table 55]

[0303] Preparation 37: (4-amino-1-benzylpiperidin-4-yl)methanol (P37) [ka]

[0304] 2M LiAlH in THF (4.27 mL, 8.54 mmol) 4 was added to a solution of 4-amino-1-benzylpiperidine-4-carboxylic acid (500 mg, 2.13 mmol) in THF (12 mL) at 0° C., then the mixture was refluxed for 2 h. The stirred reaction mixture was cooled to −10° C. and added Na 2 SO 4 *10H 2 O was carefully added in small portions until effervescence ceased. The mixture was left stirring at room temperature for 30 min, then it was filtered, the solid was washed with DCM, and the solvent was concentrated under reduced pressure to give (4-amino-1-benzylpiperidin-4-yl)methanol (P37, 400 mg, y=85%), which was used as is. [Table 56]

[0305] Preparation 38: tert-Butyl N-[1-benzyl-4-(hydroxymethyl)piperidin-4-yl]carbamate (P38) [ka]

[0306] (4-Amino-1-benzylpiperidin-4-yl)methanol (P37, 400 mg, 1.81 mmol) was dissolved in DCM (10 mL) and TEA (0.4 mL, 2.71 mmol) was added, followed by Boc 2 A solution of NH 2 O (435 mg, 1.99 mmol) was added. The resulting solution was stirred at room temperature for 2 h. 4Cl was added, the organic phase was separated, dried and concentrated. The residue was purified by FC on an NH column (eluent: Cy to Cy / EtOAc 40 / 60) to give tert-butyl N-[1-benzyl-4-(hydroxymethyl)piperidin-4-yl]carbamate (P38, 300 mg, y=52%) as a white solid. [Table 57]

[0307] Preparation 39: tert-Butyl N-[4-(hydroxymethyl)piperidin-4-yl]carbamate (P39) [ka]

[0308] To a solution of tert-butyl N-[1-benzyl-4-(hydroxymethyl)piperidin-4-yl]carbamate (P38, 300 mg, 0.936 mmol) in MeOH (7 mL) was added ammonium formate (354 mg, 5.62 mmol) and 10% Pd / C (90 mg) at room temperature, then the mixture was stirred at reflux for 1 h. The mixture was cooled to room temperature, filtered through a pad of Celite, and washed with MeOH. The solvent was removed under reduced pressure to give tert-butyl N-[4-(hydroxymethyl)piperidin-4-yl]carbamate (P39, 200 mg, y=93%) as a white solid. [Table 58]

[0309] Preparation 40: tert-Butyl N-{1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-(hydroxymethyl)piperidin-4-yl}carbamate (P40) [ka]

[0310] tert-Butyl N-[4-(hydroxymethyl)piperidin-4-yl]carbamate (P39, 75 mg, 0.326 mmol), 2-chloro-4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidine (P2, 95 mg, 0.326 mmol), and K 2 CO 3 (59 mg, 0.424 mmol) were mixed in dry DMSO (2 mL) and the mixture was shaken at 60° C. for 1 h. The mixture was cooled and diluted with EtOAc and water. The organic phase was washed several times with brine, dried, filtered and evaporated. The crude material was purified by FC on silica gel (eluent: Cy to Cy / EtOAc 75 / 25) to give tert-butyl N-{1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-(hydroxymethyl)piperidin-4-yl}carbamate (P40, 90 mg, y=57%) as a white solid. [Table 59]

[0311] Example 20: {4-amino-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl}methanol (E20) [ka]

[0312] TFA (0.5 mL) was added to a solution of tert-butyl N-{1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-(hydroxymethyl)piperidin-4-yl}carbamate (P40, 90 mg, 0.185 mmol) in 8 mL of DCM. The mixture was stirred at room temperature for 1 h, then the solvent was removed under reduced pressure. The residue was loaded onto an SCX cartridge and eluted with 1M NH in MeOH. 3 to give {4-amino-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl}methanol (E20, 50 mg, y=70%). [Table 60]

[0313] Example 21: N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-2-methylpropanamide (E21) [ka]

[0314] To a solution of isobutyric acid (5 μL, 0.054 mmol) in DCM (2 mL) was added EDC·HCl (11 mg, 0.057 mmol), HOBt (14 mg, 0.103 mmol), and TEA (14 μL, 0.103 mmol). After 10 min at room temperature, 4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E12, 20 mg, 0.0517 mmol) was added. The resulting solution was stirred at room temperature for 4 h. The solvent was evaporated and the residue was purified by FC on silica gel (eluent: Cy to Cy / AcOEt 20 / 80) to give N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-2-methylpropanamide (E21, 18.5 mg, y=78%) as a white solid. [Table 61]

[0315] Example 22: 2-Cyclopropyl-N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)acetamide (E22) [ka]

[0316] To a solution of cyclopropylacetic acid (7.5 μL, 0.081 mmol) in DCM (2 mL) was added EDC·HCl (16.5 mg, 0.086 mmol), HOBt (21 mg, 0.156 mmol), and TEA (22 μL, 0.156 mmol). After 10 min at room temperature, 4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E12, 30 mg, 0.078 mmol) was added. The resulting solution was stirred at room temperature for 4 h. The solvent was evaporated and the residue was purified by FC on silica gel (eluent: Cy to Cy / AcOEt 20 / 80) to give 2-cyclopropyl-N-({1-[4-(3-fluorophenoxy)-6(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)acetamide as a white solid (E22, 7.5 mg, y=21%). [Table 62]

[0317] Example 23: N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-2-(propan-2-yloxy)acetamide (E23) [ka]

[0318] To a solution of isopropyloxyacetic acid (9.6 mg, 0.081 mmol) in DCM (2 mL) was added EDC·HCl (16.5 mg, 0.086 mmol), HOBt (21 mg, 0.156 mmol), and TEA (22 μL, 0.156 mmol). After 10 min at room temperature, 4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E11, 30 mg, 0.078 mmol) was added. The resulting solution was stirred at room temperature for 4 h. The solvent was evaporated and the residue was purified by FC on silica gel (eluent: Cy to Cy / AcOEt 20 / 80) to give N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-2-(propan-2-yloxy)acetamide as a white solid (E23, 23.5 mg, y=62%). [Table 63]

[0319] Example 24: N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)acetamide (E24) [ka]

[0320] To a solution of acetic acid (4.7 μL, 0.078 mmol) in DCM (2 mL) was added EDC·HCl (16.5 mg, 0.086 mmol), HOBt (21 mg, 0.156 mmol), and TEA (22 μL, 0.156 mmol). After 10 min at room temperature, 4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E11, 30 mg, 0.078 mmol) was added. The resulting solution was stirred at room temperature for 4 h. The solvent was evaporated and the residue was purified by FC on silica gel (eluent: Cy to Cy / AcOEt / MeOH 0 / 90 / 10) to give N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)acetamide as a white solid (E24, 26 mg, y=77%). [Table 64]

[0321] Preparation 41: tert-Butyl 3-[({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)carbamoyl]azetidine-1-carboxylate (P41) [ka]

[0322] To a solution of 1-Boc-azetidine-3-carboxylic acid (82 mg, 0.4 mmol) in DCM (6 mL) was added EDC·HCl (82 mg, 0.423 mmol), HOBt (105 mg, 0.776 mmol), and TEA (108 μL, 0.776 mmol). After 10 min at room temperature, 4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E11, 150 mg, 0.388 mmol) was added. The resulting solution was stirred at room temperature for 12 h. The solvent was evaporated and the residue was purified by FC on silica gel (eluent: Cy to AcOEt) to give tert-butyl 3-[({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)carbamoyl]azetidine-1-carboxylate (P41, 90 mg, y=40%) as a white foam. [Table 65]

[0323] Example 25: N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)azetidine-3-carboxamide (E25) [ka]

[0324] To a solution of tert-butyl 3-[({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)carbamoyl]azetidine-1-carboxylate (P41, 85 mg, 0.15 mmol) in DCM (5 mL) was added 0.8 mL of TFA and the solution was stirred at room temperature for 1 h. The solvent and excess TFA were evaporated under reduced pressure and the residue was loaded onto an SCX cartridge and diluted with 1M NH in MeOH. 3After evaporation, N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)azetidine-3-carboxamide (E25, 70 mg, y=99%) was obtained as a white solid. [Table 66]

[0325] Example 26: N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)benzamide (E26) [ka]

[0326] To a solution of benzoic acid (16 mg, 0.135 mmol) in DCM (2 mL) was added EDC·HCl (27 mg, 0.057 mmol), HOBt (35 mg, 0.258 mmol), and TEA (36 μL, 0.258 mmol). After 20 min at room temperature, 4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E11, 50 mg, 0.129 mmol) was added. The resulting solution was stirred at room temperature for 8 h. The solvent was evaporated and the residue was purified by FC on silica gel (eluent: Cy to Cy / AcOEt 20 / 80) to give N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)benzamide (E26, 50 mg, y=79%) as a white solid. [Table 67]

[0327] Example 27: N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-1H-pyrazole-4-carboxamide (E27) [ka]

[0328] To a solution of 1H-pyrazole-4-carboxylic acid (14.5 mg, 0.135 mmol) in DCM (2 mL) was added EDC·HCl (27 mg, 0.057 mmol), HOBt (35 mg, 0.258 mmol), and TEA (36 μL, 0.258 mmol). After 20 min at room temperature, 4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E11, 50 mg, 0.129 mmol) was added. The resulting solution was stirred at room temperature for 3 h. The solvent was evaporated and the residue was purified by FC on silica gel (eluent: Cy to AcOEt) to give N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-1H-pyrazole-4-carboxamide (E27, 30 mg, y=48%). [Table 68]

[0329] Example 28: N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)pyrazine-2-carboxamide (E28) [ka]

[0330] To a solution of pyrazine carboxylic acid (17 mg, 0.135 mmol) in DCM (2 mL) was added EDC·HCl (27 mg, 0.057 mmol), HOBt (35 mg, 0.258 mmol), and TEA (36 μL, 0.258 mmol). After 20 min at room temperature, 4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E11, 50 mg, 0.129 mmol) was added. The resulting solution was stirred at room temperature for 3 h. The solvent was evaporated and the residue was purified by FC on silica gel (eluent: Cy to AcOEt) to give N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)pyrazine-2-carboxamide (E28, 17 mg, y=27%). [Table 69]

[0331] Preparation 42: tert-Butyl N-{[({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)carbamoyl]methyl}carbamate (P42) [ka]

[0332] To a solution of N-Boc-Gly (22.6 mg, 0.129 mmol) in DCM (2 mL) was added EDC·HCl (27 mg, 0.057 mmol), HOBt (35 mg, 0.258 mmol), and TEA (36 μL, 0.258 mmol). After 20 min at room temperature, 4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol (E11, 50 mg, 0.129 mmol) was added. The resulting solution was stirred at room temperature for 3 h. The solvent was evaporated and the residue was purified by FC on silica gel (eluent: Cy to AcOEt) to give tert-butyl N-{[({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)carbamoyl]methyl}carbamate (P42, 26 mg, y=37%). [Table 70]

[0333] Example 29: 2-Amino-N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)acetamide (E29) [ka]

[0334] To a solution of tert-butyl N-{[({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)carbamoyl]methyl}carbamate (P42, 26 mg, 0.048 mmol) in DCM (2 mL) was added TFA and the solution was stirred at room temperature for 1 h. The solvent and excess TFA were removed under reduced pressure and the residue was dissolved in MeOH, loaded onto an SCX cartridge, washed with MeOH and diluted with 2M NH 3Elution with 2-amino-N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)acetamide (E29, 18 mg, y=84%) is obtained. [Table 71]

[0335] Preparation 43: 5-Benzyl-1-oxa-5-azaspiro[2.4]heptane (P43) [ka]

[0336] To an ice-cooled mixture of NaH 60% dispersion (0.297 g, 7.42 mmol.) trimethylsulfoxonium iodide (1.38 g, 6.28 mmol.) in mineral oil was added DMSO (5 mL) while keeping the mixture at 10° C. After stirring for 10 min at 10° C., it was allowed to reach room temperature and left at that temperature with stirring for 1 h. A solution of 1-benzylpyrrolidin-3-one (0.92 mL, 5.71 mmol.) in DMSO (5 mL) was added via syringe. The mixture was stirred at room temperature for 3 h and then diluted with Et 2 Dilute with NH 4 The reaction was quenched by the addition of saturated aqueous Cl. The phases were separated and the aqueous phase was diluted with Et 2 Back-extracted with O. The combined organics were dried, filtered and concentrated under reduced pressure. The crude 5-benzyl-1-oxa-5-azaspiro[2.4]heptane (P43, 850 mg, y=79%) was used directly in the next step. [Table 72]

[0337] Preparation 44: 1-Benzyl-3-[(cyclopropylamino)methyl]pyrrolidin-3-ol (P44) [ka]

[0338] To a stirred solution of 5-benzyl-1-oxa-5-azaspiro[2.4]heptane (P43, 200 mg, 1.06 mmol) in MeOH (1 mL) was added dropwise cyclopropylamine (0.15 mL, 2.11 mmol) at 0° C. Once the addition was complete, the ice bath was removed and the resulting reaction mixture was stirred at room temperature overnight. The reaction mixture was then concentrated under reduced pressure, the residue was taken up with DCM, the aqueous phase was extracted, and the combined organics were then dried and concentrated under reduced pressure to give 1-benzyl-3-[(cyclopropylamino)methyl]pyrrolidin-3-ol (P44, 160 mg, y=61%). [Table 73]

[0339] Preparation 45: tert-Butyl N-[(1-benzyl-3-hydroxypyrrolidin-3-yl)methyl]-N-cyclopropylcarbamate (P45) [ka]

[0340] 1-Benzyl-3-[(cyclopropylamino)methyl]pyrrolidin-3-ol (P44, 160 mg, 0.649 mmol) was dissolved in DCM (2 mL) and TEA (0.14 mL, 0.974 mmol) was added, followed by Boc 2 A solution of NH 2 O (170 mg, 0.779 mmol) was added. The resulting solution was stirred at room temperature for 2 h. 4 Cl was added, the organic phase was separated, dried and concentrated. The residue was purified by FC on silica gel (eluent: Cy to Cy / AcOEt 70 / 30) to give tert-butyl N-[(1-benzyl-3-hydroxypyrrolidin-3-yl)methyl]-N-cyclopropylcarbamate (P45, 110 mg, y=50%) as a colorless oil. [Table 74]

[0341] Preparation 46: tert-Butyl N-cyclopropyl-N-[(3-hydroxypyrrolidin-3-yl)methyl]carbamate (P46) [ka]

[0342] To a solution of tert-butyl N-[(1-benzyl-3-hydroxypyrrolidin-3-yl)methyl]-N-cyclopropylcarbamate (P45, 110 mg, 0.317 mmol) in MeOH (3 mL) was added ammonium formate (120 mg, 1.90 mmol) and 10% Pd / C (32 mg) at room temperature, and the mixture was then stirred at reflux for 1 h. After that, the mixture was cooled to room temperature and filtered through a pad of Celite, washing with MeOH. The solvent was removed under reduced pressure to give tert-butyl N-cyclopropyl-N-[(3-hydroxypyrrolidin-3-yl)methyl]carbamate (P46, 75 mg, y=75%) as a colorless oil. [Table 75]

[0343] Preparation 47: tert-Butyl N-cyclopropyl-N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)carbamate (P47) [ka]

[0344] 2-Chloro-4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidine (P2, 85 mg, 0.293 mmol), tert-butyl N-cyclopropyl-N-[(3-hydroxypyrrolidin-3-yl)methyl]carbamate (P46, 75 mg, 0.293 mmol), and K 2 CO 3(53 mg, 0.381 mmol) were mixed in dry DMSO (2 mL) and the mixture was shaken at 60° C. for 1 h. The mixture was diluted with EtOAC and water. The organic phase was washed several times with brine, dried, filtered and evaporated. The crude material was purified by FC on a NH column (eluent: Cy to Cy / AcOEt 85 / 15) to give tert-butyl N-cyclopropyl-N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)carbamate (P47, 80 mg, y=53%). [Table 76]

[0345] Example 30: 3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol (E30) [ka]

[0346] TFA (0.3 mL) was added to a solution of tert-butyl N-cyclopropyl-N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)carbamate (P47, 60 mg, 0.117 mmol) in 3 mL of DCM. The mixture was stirred at room temperature for 1 h, then the solvent was removed under reduced pressure. The residue was loaded onto an SCX cartridge and eluted with 1M NH in MeOH. 3 Elution with 500 rpm gave 3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol (E30, 40 mg, y=83%) as a colourless oil. [Table 77]

[0347] Examples 31 and 32: (3S or 3R)-3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol (E31) and (3R or 3S)-3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol (E32) [ka]

[0348] 3-[(Cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol (E30, 30 mg) was subjected to chiral preparative HPLC to separate the single enantiomers.

[0349] Preparative HPLC conditions and results: [Table 78]

[0350] Production: (3S or 3R)-3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol (E3, single enantiomer: enantiomer 1, 8.4 mg, y=28%) 100% ee (3R or 3S)-3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol (E32, single enantiomer: enantiomer 2, 7.3 mg, y=24%) 100% ee

[0351] Preparation 48: 3-(Aminomethyl)-1-benzylpyrrolidin-3-ol (P48) [ka]

[0352] To a stirred solution of 5-benzyl-1-oxa-5-azaspiro[2.4]heptane (P43, 850 mg, 4.49 mmol) in MeOH (5 mL) at 0 °C was added NH 4 A 28% aqueous solution of OH (10 mL) was added dropwise. Once the addition was complete, the ice bath was removed and the resulting reaction mixture was stirred at room temperature overnight. The reaction mixture was then concentrated under reduced pressure, the residue taken up with DCM, the aqueous phase extracted, the aqueous phase back extracted with DCM, and the combined organics dried and concentrated under reduced pressure to give 3-(aminomethyl)-1-benzylpyrrolidin-3-ol (P56, 900 mg, y=quantitative). [Table 79]

[0353] Preparation 49: tert-Butyl N-[(1-benzyl-3-hydroxypyrrolidin-3-yl)methyl]carbamate (P49) [ka]

[0354] 3-(Aminomethyl)-1-benzylpyrrolidin-3-ol (P48, 900 mg, 4.49 mmol) was dissolved in DCM (10 mL) and TEA (0.94 mL, 6.74 mmol) was added, followed by Boc 2 A solution of NH 2 O (1.18 g, 5.39 mmol) was added. The resulting solution was stirred at room temperature for 2 h. 4 Cl was added, the organic phase was separated, dried and concentrated. The residue was purified by FC on silica gel (eluent: Cy to AcOEt) to give tert-butyl N-[(1-benzyl-3-hydroxypyrrolidin-3-yl)methyl]carbamate (P49, 470 mg, y=34%) as a colorless oil. [Table 80]

[0355] Preparation 50: tert-Butyl N-[(3-hydroxypyrrolidin-3-yl)methyl]carbamate (P50) [ka]

[0356] To a solution of tert-butyl N-[(1-benzyl-3-hydroxypyrrolidin-3-yl)methyl]carbamate (P49, 470 mg, 1.53 mmol) in MeOH (10 mL) was added ammonium formate (580 mg, 9.20 mmol) and 10% Pd / C (155 mg) at room temperature, then the mixture was stirred at reflux for 3 h. The mixture was cooled to room temperature, filtered through a pad of Celite, and washed with MeOH. The solvent was removed under reduced pressure to give tert-butyl N-[(3-hydroxypyrrolidin-3-yl)methyl]carbamate (P50, 350 mg, y=quantitative) as a colorless oil. [Table 81]

[0357] Preparation 51: tert-Butyl N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)carbamate (P51) [ka]

[0358] 2-Chloro-4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidine (P2, 200 mg, 0.925 mmol), tert-butyl N-[(3-hydroxypyrrolidin-3-yl)methyl]carbamate (P50, 291 mg, 0.925 mmol), and K 2 CO 3(166 mg, 1.203 mmol) were mixed in dry DMSO (4 mL) and the mixture was shaken at 60° C. for 2 h. The mixture was diluted with EtOAC and water. The organic phase was washed several times with brine, dried, filtered and concentrated. The crude material was purified by FC on silica gel (eluent: Cy to Cy / AcOEt 80 / 20) to give tert-butyl N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)carbamate (P51, 200 mg, y=46%) as a white solid. [Table 82]

[0359] Example 33: 3-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol (E33) [ka]

[0360] TFA (0.32 mL) was added to a solution of tert-butyl N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)carbamate (P51, 200 mg, 0.423 mmol) in 8 mL of DCM. The mixture was stirred at room temperature for 1 h, then the solvent was removed under reduced pressure. The residue was loaded onto an SCX cartridge and eluted with 1M NH in MeOH. 3 Elution with 5% CO gave 3-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol (E33, 160 mg, y=quantitative) as a colourless oil. [Table 83]

[0361] Example 34: N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)-2-methylpropanamide (E34) [ka]

[0362] To a solution of isobutyric acid (13 μL, 0.141 mmol) in DCM (4 mL) was added EDC HCl (30 mg, 0.155 mmol), HOBt (36 mg, 0.268 mmol), and TEA (37 μL, 0.268 mmol). After 10 min at room temperature, 3-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol (E33, 50 mg, 0.134 mmol) was added. The resulting solution was stirred at room temperature for 4 h. The solvent was evaporated and the residue was purified by FC on silica gel (eluent: Cy to Cy / AcOEt 30 / 70) to give N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)-2-methylpropanamide (E34, 59 mg, y=95%) as a colorless oil. [Table 84]

[0363] Preparation 52: tert-Butyl 3-[({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)carbamoyl]azetidine-1-carboxylate (P52) [ka]

[0364] To a solution of 1-Boc-azetidine-3-carboxylic acid (28 mg, 0.141 mmol) in DCM (4 mL) was added EDC HCl (30 mg, 0.155 mmol), HOBt (36 mg, 0.268 mmol), and TEA (0.037 mL, 0.268 mmol). After 10 min at room temperature, 3-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol (E33, 50 mg, 0.134 mmol) was added. The resulting solution was stirred at the same temperature overnight. The solvent was evaporated and the residue was purified by FC on silica gel (eluent: Cy to AcOEt) to give tert-butyl 3-[({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)carbamoyl]azetidine-1-carboxylate (P52, 45 mg, y=61%) as a white solid. [Table 85]

[0365] Example 35: N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)azetidine-3-carboxamide (E35) [ka]

[0366] TFA (0.3 mL) was added to a solution of tert-butyl 3-[({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)carbamoyl]azetidine-1-carboxylate (P52, 45 mg, 0.081 mmol) in 3 mL of DCM. The mixture was stirred at room temperature for 1 h, then the solvent was removed under reduced pressure. The residue was loaded onto an SCX cartridge and eluted with 1M NH in MeOH. 3Elution with 500 rpm gave N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)azetidine-3-carboxamide as a white solid (E35, 36 mg, y=98%). [Table 86]

[0367] Example 36: 4-(3-fluorophenoxy)-2-{3H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl}-6-(trifluoromethyl)pyrimidine (E36) [ka]

[0368] 3H,4H,5H,6H,7H-Imidazo[4,5-c]pyridine hydrochloride (50 mg, 0.31 mmol), 2-chloro-4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidine (P2, 91 mg, 0.31 mmol), and K 2 CO 3 (98 mg, 0.713 mmol) was heated at 100° C. for 1 h. After cooling at room temperature, EtOAc and water were added and the product was extracted into the organic phase. The organic phase was dried, evaporated and the residue was purified by FC on an NH column (eluent: DCM to DCM / MeOH 90 / 10) to give 4-(3-fluorophenoxy)-2-{3H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl}-6-(trifluoromethyl)pyrimidine (E36, 18 mg, y=15%) as a white solid. [Table 87]

[0369] Preparation 53: 1-Benzyl-6-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-decahydro-1,6-naphthyridine (P53) [ka]

[0370] In a sealed vessel, 1-benzyl-decahydro-1,6-naphthyridine (51 mg, 0.22 mmol), 2-chloro-4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidine (P2, 65 mg, 0.22 mmol), and K were dissolved in DMSO (0.9 mL). 2 CO 3 (39 mg, 0.29 mmol) was heated at 90° C. and shaken at this temperature for 1.5 h. After cooling at room temperature, EA and water were added, the organic phase was washed with water, dried, evaporated and the crude product was purified by FC on an NH column (eluent: Cy to Cy / EA90 / 10) to give 1-benzyl-6-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-decahydro-1,6-naphthyridine (P53, 56 mg, y=52%). [Table 88]

[0371] Example 39: 6-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-decahydro-1,6-naphthyridine hydrochloride (E39) [ka]

[0372] Step a To a solution of 1-benzyl-6-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-decahydro-1,6-naphthyridine (P53, 56 mg, 0.11 mmol) in MeOH (3.5 mL), was added HCOONH 4 (44 mg) and 10% Pd / C (15 mg) were added at room temperature, and the mixture was then stirred at reflux. After 1.5 h, the reaction mixture was filtered through Celite and the solvent was removed under vacuum. The residue was dissolved in DCM and the organic solution was washed twice with water and added with Na2 SO 4 and the solvent was removed under reduced pressure to give the crude material which was purified by FC on a NH cartridge (eluent: Cy to Cy / EA60 / 40) to give 6-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-decahydro-1,6-naphthyridine (24 mg).

[0373] Step B 6-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-decahydro-1,6-naphthyridine (from step a, 24 mg) was dissolved in DCM (0.1 mL) and 2N HCl (0.031 mL) was added. The mixture was concentrated under reduced pressure and the residue was triturated with ether and dried under vacuum to give 6-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-decahydro-1,6-naphthyridine hydrochloride (E39, 24 mg, y=46%). [Table 89]

[0374] biological methods The ability of the compounds of formula I to inhibit the dopamine transporter can be determined using the following biological assay.

[0375] Measurement of affinity for human transporters DAT, NET, and SERT The affinity of the compounds of the present invention for the human dopamine transporter (DAT), human norepinephrine transporter (NET), and human serotonin transporter (SERT) can be determined by the assays described below. The affinity is expressed in terms of the inhibition constants of the compounds of the present invention for the DAT, NET, and SERT, and is typically calculated by the IC 2 obtained from competition experiments using the Cheng-Prusoff equation (Cheng and Prusoff, Biochem. Pharmacol. 22:3099, 1973). 50In the context of the present invention, the pKi value (corresponding to the negative logarithm of K) is used instead of K. The pKi is estimated to be accurate only to about 0.3 log units.

[0376] Scintillation Proximity Assay (SPA) for Human DAT, NET, and SERT Binding a) Membrane Preparation Chinese hamster ovary (CHO) cells stably expressing human DAT (hDAT-CHO), human NET (hNET-CHO), or human SERT (hSERT-CHO) are used for membrane preparations for radioligand binding assays using the Scintillation Proximity Assay (SPA) technique. Each cell line is individually cultured in F-12K Nutrient Mixture containing 10% fetal bovine serum (FBS) supplemented with 450 μg / ml G-418. When the cells reached 70-80% confluence, 3 mM sodium butyrate was added to the cell culture medium. After 24 hours of incubation, the medium was removed and the cells were detached using Versen's solution (DAT) or by scraping (NET and SERT). The cell suspension was centrifuged at 41,000 g for 10 minutes at 4°C. The resulting pellet is resuspended in 15x volume of ice-cold buffer (20 mM HEPES, 145 mM NaCl, 5 mM KCl, pH 7.3), homogenized using an Ultra Turrax homogenizer, and centrifuged as before. The resulting membrane pellet is resuspended in up to 15x volume of ice-cold buffer, incubated at 37°C for 20 min, and centrifuged at 41,000g as before. The final membrane pellet is resuspended in 5-10x volume of ice-cold buffer, distributed into 0.5 ml aliquots, and stored at -80°C until use. The protein concentration of each preparation is determined using a Bio-Rad Protein Assay kit.

[0377] b) Competitive binding experiments using scintillation proximity assay (SPA) for human DAT, NET, and SERT The affinity of the compounds of the present invention for the human DAT, NET, or SERT transporter was determined by measuring the [ 3 H]WIN-35,428, or [ 3 H]nisoxetine, or [ 3 H]citalopram binding assay. Final assay volume is 50 μL in a 384-well plate.

[0378] Briefly, 0.5 μL of test compound in undiluted DMSO or 0.5 μL of DMSO for total binding (TB) or 0.5 μL of 1 mM indatraline for non-specific binding (NSB) (final concentration 10 μM) are added to the assay plate. 30 μg / mL or 10 μg / mL or 25 μg / mL of DAT, NET, SERT membranes, respectively; 5 nM of [ for DAT, NET, SERT assays, respectively] 3 H]WIN-35,428 or 5 nM [ 3 H]nisoxetine or 1 nM [ 3 50 μL of SPA mixture containing [H]citalopram; 2.5 mg / mL or 1 mg / mL or 4 mg / mL WGA-PVT SPA beads (PerkinElmer RPNQ0001) for DAT, NET, SERT assays, respectively, are added to each well. All components are added in assay buffer (20 mM HPEPS pH 7.4, 145 mM NaCl, 5 mM KCl, 0.01% Pluronic F-127). 0.02% BSA was used only for DAT binding. Plates are sealed with Topseal A and centrifuged at 800 rpm for 1 min. Plates are placed in a 1450 Microbeta TriLux (Perkin-Elmer) plate reader and incubated at room temperature for at least 4 h or overnight before counting radioactivity. Curve fitting and IC were performed using the four-element model in XLfit (IDBS, Guilford, UK) for Microdoft Excel (Microsoft, Redmond, WA). 50 Estimate the following.

[0379] Functional uptake assay in hDAT-CHO cells The potency of the compounds of the invention to block DAT function is measured using an uptake assay in a recombinant CHO cell line expressing human DAT (hDAT-CHO). Potency is measured using SPA technology in a 384-well format to measure the uptake of [ 3 3H]-dopamine uptake inhibition was tested to determine pIC 50 Briefly, on the day of the experiment, hDAT-CHO cells are detached using Verzen solution and added to the SPA mixture (75,000 cells / mL). The SPA mixture is made up of assay buffer (20 mM HEPES, 145 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2). 2 , and 1 g / L glucose, pH 7.3) containing the following components: 0.02% w / v Pluronic F127, 2 mg / mL SPA imaging beads (RPNQ0260, PerkinElmer), 10 μM pargyline, and 80 nM [ 3 H]-dopamine. The SPA mixture is added at 50 μl per well to a 384-well plate containing 0.5 μL of test compound in undiluted DMSO per well, or 0.5 μL of DMSO (control uptake), or 0.5 μL of the standard inhibitor indatraline (10 μM at the end of the assay). The plate is sealed with Top-seal A and read using a Viewlux instrument (Perkin-Elmer) at time intervals of 15-30 min. The first highest signal is used for data analysis.

[0380] Measuring effects on hERG channels by recording tail currents with in vitro Rapid ICE™ The potency of the compounds of the present invention to inhibit human ERG potassium channel (hERG) tail currents is evaluated in recombinant HEK293 cell lines stably transfected with hERG cDNA using the Rapid ICE™ (rapid ion channel electrophysiology) assay. Rapid ICE™ is an automated patch clamp assay that utilizes the PatchXpress 7000A system (Molecular Devices Corporation) or the QPatch HTX system (Sophion Bioscience A / S).

[0381] Briefly, cells are cultured for 24-72 hours in minimal essential medium supplemented with 10% FBS, 1% non-essential amino acids, 1% sodium pyruvate, and 2 mM L-glutamine prior to recording. On the day of the experiment, cells are detached with TrypLE and prepared to be loaded onto the instrument. For PatchXpress, cells are finally resuspended in 150 μl of extracellular buffer, whereas for QPatch, cells are resuspended in 7 ml of serum-free medium containing 25 mM Hepes and soybean trypsin inhibitor and immediately placed into the cell storage tank of the instrument. The composition of the extracellular buffer is as follows (in mM): NaCl 137; KCl 4; CaCl2 1.8; MgCl2 1.0; D-glucose 10; N 2 hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) 10; pH 7.4 with 1 M NaOH. The composition of the pipette solution is as follows (mM): KCl 130; MgCl2 1.0; Ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) 5; MgATP 5; HEPES 10; pH 7.2 with 1M KOH. The voltage protocol includes the following steps: step from -80mV to -50mV for 200ms, +20mV for 4.8s, step to -50mV for 5s, then step to a holding potential of -80mV. Compounds of the invention are dissolved in DMSO and diluted in extracellular buffer to achieve final test concentrations (0.1, 1, and 10μM) in 0.1% DMSO. The voltage protocol is run and recorded continuously throughout the experiment. Vehicle corresponding to 0.1% DMSO in extracellular buffer is then applied for 3 minutes, followed by the test substance in triplicate. The standard combined exposure time is 5 minutes. The average of the tail current amplitude values ​​recorded from four consecutive voltage pulses is used to calculate the effect of the test substance for each cell by calculating the residual current compared to vehicle pretreatment (% control). Data are reported as % inhibition for each concentration tested, IC 50 Values ​​are estimated using DataXpress or QPatch software. At least two cells are tested, more in case of divergent results.

[0382] Representative compounds of the present invention were tested according to the procedures described above. The results are listed in Table 1 below. Table 1 [Table 90] [Table 91]

[0383] While the foregoing specification teaches the principles of the invention by providing examples for purposes of illustration, it will be understood that practice of the invention encompasses all ordinary variations, adaptations, and / or modifications that fall within the scope of the following claims. References 1 Wise RA, Annu Rev Neurosci.1996;19:319-3402 Cohen NJ et al., Psychopharmacologia.1971;22(3):282-2943 Leibowitz SF et al., Brain Res Bull.1986;17(5):681-689.4 Hartmann E et al. al.,Psychopharmacology(Berl).1976 10;50(2):171-1755 Lader MH,J Clin Psychiatry.1996;57 Suppl 2:39-446 Montejo-Gonzalez AL et al.,J Sex Marital Ther.1997;23(3):176-1947 Olfson M et al.,Arch Gen Psychiatry.2006 Aug;63(8):865-8728 Dworkin N,J Am Acad Child Adolesc Psychiatry.2005;44(6):5109 Denolle T et al.,Clin Pharmacol Ther.1999;66(3):282-28710 Nieoullon A,Prog Neurobiol.2002;67(1):53-8311 Cornish RS et al.,Pharm Res.2005;22(4):603-61212 Cook EH Jr et al.,Am J Hum Genet.1995;56(4):993-99813 Van Gaalen MM et al.,Biol Psychiatry.2006;60(1):66-7314 Yoon et al.,J Neurol Sci.2007;255(1-2):50-5615 Cheon et al.,Psychiatry Res.2004;130(1):85-9516 Kim CH et al.,Eur J Nucl Med Mol Imaging.2003;30(12):1637-164317 Grigorenko EL et al.,Aggress Behav.2010;36(3):158-17618 Amsterdam et al.,J Affect Disord.2012;141(2-3):425-43119 Hsiao et al.,Psychiatry Res.2013;211(1):72-7720 Baldwin DS et al.,Br J Psychiatry.2013;202:396-39721 Abler B et al.,Neuropsychopharmacology.2011;36(9):1837-184722 Segman et al.,Mol Psychiatry.2002;7(8):903-723 Devos D et al.,J Neurol Neurosurg Psychiatry.2007;78(5):470-47524 Espay et al.,Neurology.2011;76(14):1256-126225 Auriel et al.,Clin Neuropharmacol.2006;29(1):15-1726 Baumann MH et al.,J Pharmacol Exp Ther.1994;271(3):1216-122227 Rothman RB et al.,Pharmacol Biochem Behav.1991;40(2):387-39728 Wang GJ et al., Pharmacol Biochem Behav. 1991;40(2):387-39729 Michaelides M et al.,Int Rev Psychiatry.2012;24(3):211-21830 Bello et al.,Brain Res Bull.2006;70(4-6):422-42931 Shinohara M et al.,J Psychiatry Neurosci.2004;29(2):134-13732 Slama et al.,Diabete Metab.1978;4(3):193-19933 Remy P et al.,Curr Opin Neurol.2003;16 Suppl 2:S37-4134 Berrios GE,Compr Psychiatry 1990;31(2):140-15135 Harris JD,Curr Opin Support Palliat Care 2008;2(3):180-18636 Lacerda et al.,J Cardiovasc Electrophysiol.2010;21(3):301-31037 Campbell VC et al.,J Pharmacol Exp Ther.2005;315(2):631-64038 Zou MF et al.,J Med Chem.2006;49(21):6391-639939 Li SM et al.,J Pharmacol Exp Ther.2011;336(2):575-585.

Claims

1. A compound according to formula I, 【Chemistry 1】 During the ceremony, A is alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O) ２ Alkyl, OH, F, Cl, -CN, OCF ３ , C.F. ３ , N.R. １３ C.O.R. １４ , and N.R. １３ R １４ selected from phenyl, pyridyl, and pyrimidinyl, optionally substituted with 1, 2, or 3 substituents independently selected from B is alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O) ２ Alkyl, OH, F, Cl, -CN, OCF ３ , C.F. ３ , N.R. １３ C.O.R. １４ , and N.R. １３ R １４ phenyl, optionally substituted with 1, 2, or 3 substituents independently selected from L is O; R １ is alkyl, alkoxy, CH ２ selected from OH, OH, F, and Cl; R ２ is N.R. ７ R ８ , C.R. １１ R １２ N.R. ７ R ８ , (CR １１ R １２ ) ２ N.R. ７ R ８ , and (CR １１ R １２ ) ３ N.R. ７ R ８ is selected from R ２ is NR ７ R ８ If R １ is alkyl, or CH ２ OH, R ３ is H, R ４ is H, R ７ and R ８ are independently H, alkyl, cycloalkyl, heterocyclyl, and C(O)R １０ is selected from R ７ But C(O)R １０ If R ８ is H or alkyl, or R ７ and R ８ may be taken together with the nitrogen atom to which they are attached to form a heterocyclyl; R ９ａ , R ９ｂ , R ９ｃ , R ９ｄ , R ９ｅ , and R ９ｆ is independently selected from H and alkyl; R １０ is selected from alkyl, aryl, heterocyclyl, and heteroaryl; --- is absent, m is 0, 1, or 2, and when m is 2, n is 0; n is 0, 1, or 2, and when n is 2, m is 0; Alkyl is an alkyl group having up to six carbon atoms (C １ -C ６ ) or a straight chain saturated hydrocarbon having 3 to 6 carbon atoms (C ３ -C ６ ) branched saturated hydrocarbon, where alkyl is S-alkyl, S(O)alkyl, S(O) ２ Alkyl, cycloalkyl, heterocyclyl, alkoxy, OH, -CN, CF ３ , COOR １３ , C.O.R. １３ R １４ , F, Cl, NR １３ C.O.R. １４ , and N.R. １３ R １４ optionally substituted with 1, 2, 3, 4, or 5 substituents selected from Cycloalkyl is an alkyl group having 3 to 7 carbon atoms (C ３ -C ７ ) is a monocyclic saturated hydrocarbon, and cycloalkyl is S-alkyl, S(O)alkyl, S(O) ２ Alkyl, alkyl, alkoxy, OH, -CN, CF ３ , COOR １３ , C.O.R. １３ R １４ , F, Cl, and NR １３ R １４ and optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Heterocyclyl is N, S, O, and NR １３ and heterocyclyl is an alkyl, cycloalkyl, alkoxy, S-alkyl, S(O)alkyl, S(O)alkyl, S(O) ２ Alkyl, oxo, OH, F, Cl, -CN, OCF ３ , C.F. ３ , N.R. １３ C.O.R. １４ , and N.R. １３ R １４ and optionally substituted with 1, 2, or 3 substituents independently selected from Heteroaryl is N, NR １３ Heteroaryl is an aromatic ring having 5 or 6 members, containing 1, 2, or 3 ring members independently selected from , S, and O, and heteroaryl is an alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O) ２ Alkyl, OH, F, Cl, -CN, OCF ３ , C.F. ３ , N.R. １３ C.O.R. １４ , and N.R. １３ R １４ and optionally substituted with 1, 2, or 3 substituents independently selected from Alkoxy is an alkyl group having 1 to 6 carbon atoms (C １ -C ６ ) or a straight chain O-linked hydrocarbon having 3 to 6 carbon atoms (C ３ -C ６ ) branched O-linked hydrocarbon, and alkoxy is S-alkyl, S(O)alkyl, S(O) ２ Alkyl, alkyl, OH, -CN, CF ３ , COOR １３ , C.O.R. １３ R １４ , F, Cl, NR １３ C.O.R. １４ , and N.R. １３ R １４ and optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R １１ , R １３ , and R １４ is independently selected from H and alkyl; R １２ is alkyl; Compounds, and pharma- ceutically acceptable salts thereof.

2. R １ is selected from alkyl, and F; R ２ But, CR １１ R １２ N.R. ７ R ８ That is, The compound of claim 1.

3. R １ The compound of claim 1 , wherein

4. R ２ CH ２ N.R. ７ R ８ 2. The compound of claim 1,

5. 2. The compound of claim 1, wherein n is 1 and m is 0 or 1.

6. R ９ａ , R ９ｂ , R ９ｃ , R ９ｄ , R ９ｅ , and R ９ｆ The compound of claim 1 , wherein all are H.

7. The compound of claim 5 , wherein m is 1.

8. 2. The compound of claim 1, wherein the compound according to formula I is represented by the formula: 【Chemistry 2】 (In the formula, A, B, L, R １ , R ２ and m are as defined in any one of claims 1 to 7.

9. A is alkyl, F, Cl, -CN, and CF ３ phenyl, pyridyl, or pyrimidinyl, optionally substituted with 1, 2, or 3 substituents independently selected from The compound of claim 1 , wherein the pyridyl and pyrimidinyl are attached to the N-containing ring through the 2-position of the pyridyl and pyrimidinyl.

10. A is alkyl, F, Cl, -CN, and CF ３ phenyl, pyridyl, or pyrimidinyl, substituted by 1, 2, or 3 substituents independently selected from The compound of claim 1 , wherein the pyridyl and pyrimidinyl are attached to the N-containing ring through the 2-position of the pyridyl and pyrimidinyl.

11. The compound of claim 1, wherein A is selected from the group consisting of: 【Chemistry 3】 【Chemistry 4】

12. The compound of claim 1, wherein B is selected from the group consisting of: 【Chemistry 5】

13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12 and a pharma- ceutically acceptable excipient.

14. 13. An inhibitor of the dopamine transporter, comprising a compound according to any one of claims 1 to 12, for use in the treatment or prevention of a condition, disease or disorder ameliorated by inhibition of the dopamine transporter.

15. 15. The inhibitor for use according to claim 14, wherein the condition, disease or disorder is selected from sexual dysfunction, emotional disorders, anxiety, depression, Tourette's syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorders, substance abuse, smoking cessation, eating disorders, chronic or persistent fatigue, and impulse control disorders.

16. 15. The inhibitor for use according to claim 14, wherein the condition, disease or disorder is selected from attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), binge eating disorder, and fatigue associated with a condition selected from the group consisting of chronic fatigue syndrome, post-viral fatigue syndrome, HIV, multiple sclerosis, amyotrophic lateral sclerosis (ALS), myasthenia gravis, sarcoidosis, cancer, chemotherapy treatment, celiac disease, irritable bowel syndrome, spondyloarthropathy, fibromyalgia, arthritis, infectious diseases, diabetes, eating disorders, Parkinson's disease, sleep disorders, stroke, mood disorders, drug abuse, and alcohol abuse.

Images